



**CANNAMERICA BRANDS CORP.**

**ANNUAL REPORT**

**For the Year Ended**

**March 31, 2021**

## **CannAmerica Brands Corp.**

### **Management's Discussion and Analysis for the Year Ended March 31, 2021**

All amounts expressed in CAD dollars, unless otherwise stated)

---

## **INTRODUCTION**

The following management discussion and analysis ("MD&A") of the results of operations and financial condition of CannAmerica Brands Corp. ("CannAmerica") should be read in conjunction with the consolidated financial statements for the years ended March 31, 2021 and 2020 of CannAmerica and the accompanying notes thereto for CannAmerica, CannAmerica Holdings Corp. and DAFF International, LLC. The consolidated financial statements comprise the financial statements of CannAmerica and its legal subsidiaries (collectively referred to as the "Company").

The financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS") and all amounts are expressed in Canadian dollars unless noted otherwise. The effective date of this MD&A is October 5, 2021.

## **DESCRIPTION OF BUSINESS**

CannAmerica Brands Corp. (formerly Transform Capital Corp.) ("CannAmerica") was incorporated in the province of British Columbia on March 13, 2017, under the Business Corporations Act of British Columbia. CannAmerica's head office and its registered and records office is located at 10th Floor, 595 Howe Street, Vancouver, British Columbia, V6C 2T5.

On May 30, 2018, CannAmerica entered into an agreement with the shareholders of CannAmerica Holdings Corp. ("CannAmerica Holdings") whereby 100% of the common shares and warrants of CannAmerica Holdings were exchanged for common shares of CannAmerica (the "CannAmerica Holdings Acquisition"). The CannAmerica Holdings Acquisition is considered a reverse takeover of a non-operating company whereby CannAmerica Holdings, the legal subsidiary, has been determined to have acquired control of CannAmerica and to be the acquirer for accounting purposes. In accordance with the principles of reverse takeover accounting, CannAmerica will report the operations of CannAmerica Holdings and its related historical comparatives as its continuing business, except for the legal capital shown in the Consolidated Statements of Changes in Shareholders' Equity, which have been adjusted to reflect the share capital of CannAmerica.

CannAmerica Holdings was incorporated in the Province of British Columbia on December 11, 2017, under the Business Corporations Act of British Columbia and was formed to identify an appropriate business for acquisition or investment. CannAmerica Holdings completed a business combination on May 18, 2018, and now owns a portfolio of brands in the medical and recreational cannabis space in the United States through its wholly owned subsidiary DAFF International, LLC ("DAFF"). The Company's principal business is to build on and maximize the value of its brands by promoting, marketing and licensing these brands through various distribution channels, including dispensaries, wholesalers and distributors. The Company currently has four brand licensing agreements with licensees in the states of Colorado, Nevada, Oklahoma, and Massachusetts. On October 15, 2018, the Company listed on the Canadian Securities Exchange ("CSE") under the ticker symbol "CANA".

### **Brands and Licensees**

The Company's brand in the cannabis space, CannAmerica, is licensed to manufacturers and wholesale licensees in the United States. The brand has been in existence since early 2016.

As of the date of this report, the Company has four branded licensing agreements with licensees in the states of Colorado, Nevada, Oklahoma, and Massachusetts.

**Arsenal Oils and Extracts:** Arsenal Oils and Extracts is a Veteran-owned, Colorado licensed marijuana extraction and wholesale distribution company. Arsenal's mission is to create, innovate, and supply quality products to cannabis consumers and wholesalers throughout the great state of Colorado. With this core philosophy, the team at Arsenal pushes the boundaries beyond what is accepted as the status quo in the marijuana industry as a manufacturer of superior quality concentrates with safety in mind. The staff at Arsenal are adamant connoisseurs of everything that makes America great including enjoying these magnificent times of legally producing, selling, and consuming cannabis.

**CannAmerica Brands Corp.**

**Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

**Flower One Holdings Inc.:** Flower One is one of the leading cannabis cultivators, producers and innovators in the highly lucrative Nevada market. Flower One owns and operates a 25,000 square foot cultivation and production facility in North Las Vegas, with nine grow rooms, and owns the established NLV Organics consumer brand of cannabis products. The Company is also rapidly converting its 455,000 square-foot greenhouse and production facility, which is the largest in the State of Nevada, for cultivating and processing high-quality cannabis at scale. Combined, the flagship greenhouse facility and production facility (once fully operational) and the North Las Vegas facility provide Flower One with 480,000 square feet of capacity for cultivation and processing, production and high-volume packaging of dry flower, cannabis oils, concentrates and infused products. The Company is fully licensed for medical marijuana cultivation and production, as well as recreational marijuana cultivation and production in the state of Nevada and currently holds licensing agreements with their Brand Partners, Flyte Concentrates, Rapid-Dose Therapeutics' Quick Strip, Old Pal, Palms, HUXTON, and CannAmerica Brands.

**THC, Inc.:** THC Total Herbal Care (THC) is licensed to cultivate, process, and dispense cannabis in Oklahoma. THC provides products to help patients improve their quality of life, aiming to deliver only the finest premium cannabis solutions and medicine.

**Canna Provisions Inc.:** Located in Massachusetts, Canna Provisions is the next generation of cannabis dispensary focusing on a unique and thoughtful customer experience. Founded by established industry pioneers with extensive cultivation, regulation and consumer sales experience, Canna Provisions stores provide a broad range of top-grade craft cannabis products that are locally sourced and thoughtfully produced.

The Company generates revenue through license agreements whereby licensees are granted rights to utilize the Brands, substrate, packaging and labelling, and related intellectual property. Licensees are responsible for assembling the branded products by infusing the substrate with clear cannabis distillate and packaging for sale to the end consumer. The Company is not involved in the cultivation, extraction, or infusion of any cannabis or cannabis derivatives.

The Company's license agreements require a licensee to pay royalties to the Company based on a fixed price per unit or as a percentage of the licensee sales and apply to specific geographical territories and distribution channels in which the licensed products may be sold. The Company's agreements also contain an upfront fee component, where the licensee agrees to pay a license fee to CannAmerica in exchange for an exclusive license to manufacture and distribute the Company's products during the term of the agreement. Fees are \$500k USD for recreational licensees and \$250k USD for medical, with 50% of the fee due upon execution of the agreement and 50% due upon the one-year anniversary of the agreement.

Other significant terms outlined in the license agreements typically include the duration of the contract, payment frequency and applicable minimum thresholds for purchase.

The Company intends to expand primarily through additional licenses in new territories, the development and acquisition of new brands, and through partnerships and other arrangements. The Company aims to acquire additional well-known consumer brands in the cannabis space with high potential for growth and strong brand awareness and select licensees who have demonstrated the ability to cultivate, manufacture, produce and sell quality products in their respective licensed categories and territories.

For the year ended March 31, 2021, DAFF revenues were concentrated within four licensees: TR Scientific (previous licensee in Colorado) and Arsenal Oils and Extracts in Colorado, Flower One in Nevada, THC in Oklahoma and Canna Provisions in Massachusetts. Revenues included fees earned from packaging to licensees along with the recognition of the initial upfront fees from Flower One, THC, Canna Provisions, and Leaf & Mark.

In February 2019, the Company signed a new brand licensing agreement with a subsidiary of Flower One Holdings Inc. (CSE: FONE) (OTCQB: FLOOF) in the state of Nevada. This brand licensing agreement replaces the Company's previous brand licensing agreement with Matrix NV, which terminated during March 2019. Flower One began placing orders of the Company's branded products in April 2019 and receiving payment on orders in June 2019.

## **CannAmerica Brands Corp.**

### **Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

The Company expects to achieve revenue growth from its existing licensees and through obtaining additional license agreements in new territories. On June 28, 2019, the Company entered into a long-term licensing agreement and brand partnership with THC Total Herbal Care Corporation ("THC") under which THC will have an exclusive license to manufacture and distribute CannAmerica branded cannabis infused gummy products, disposable vape pens, distillate droppers and shatter and wax concentrate product in Oklahoma.

Terms of the Agreement include:

- The initial term will be for a period of 5 years.
- 50% upfront license fee paid within two business days of the agreement with the remaining 50% paid on the one-year anniversary date.
- The Licensee will purchase all un-infused consumable ingredients, packaging supplies, and branded hardware exclusively from the Company.
- THC will follow formulations and processes provided by the Company.
- During the first 180 days of the initial term, THC will employ two full-time salespeople in Oklahoma to promote, market, advertise, and sell the Licensed Products.

On October 28, 2019, CannAmerica entered into a long-term licensing agreement and brand partnership with Canna Provisions Inc. under which the Licensee will have an exclusive license to manufacture and distribute CannAmerica branded cannabis infused gummy products and Live Labs branded concentrate products in the Commonwealth of Massachusetts. Live Labs is a brand created by the founders of CannAmerica, wholly owned by the Company, and is being introduced in the Northeastern United States recreational cannabis marketplace.

Terms of the Agreement are as follows:

- the initial term will be for a period of 3 years;
- Canna Provisions Inc. will follow formulations and processes provided by the Company;
- If Licensor wishes to grant a license to a third-party licensee with respect to the marketing, sale, and distribution of Licensed Products in New York, Connecticut, Vermont, New Hampshire, Maine, or Rhode Island, Canna Provisions Inc. has the right of first refusal;
- during the first 180 days of the initial term, the licensee will employ one full-time salesperson in Massachusetts to promote, market, advertise, and sell the Licensed Products;
- In addition to the fees contained in the agreement, a licensee fee of US\$500,000 due to the Company in installments, payable as follows:
  - US\$50,000 within two days after the mutual execution of the Agreement;
  - US\$200,000 in installment payments (US\$50,000 per month for a period of four months) with the first installment due two days after the Licensee obtains a license for its production facility from the Commonwealth of Massachusetts;
  - US\$250,000 due 12 months after the Effective date of the Agreement
- The Company is obligated to issue \$500,000 worth of common shares to Canna Provisions Inc. with \$250,000 worth of common shares issuable within two days after the US\$200,000 installment is made and the second \$250,000 worth of common shares issuable within two days of the final US\$250,000 being made from Canna Provisions Inc. to the Company.

On August 26, 2020, the Company announced that it entered into a long-term licensing agreement and brand partnership with Arsenal Oils and Extracts under which Arsenal will have an exclusive license to manufacture and distribute CannAmerica branded products and Live Labs in Colorado.

## **CannAmerica Brands Corp.**

### **Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

Terms of the Agreement include:

- The initial term will be for a period of 5 years;
- Payments are a flat fee per unit based on the use of the Company's Intellectual Property;
- The Licensee will purchase all consumable ingredients, packaging supplies, and branded hardware exclusively from the Company;
- The Licensee will follow formulations and processes provided by the Company; and
- The Licensee will distribute CannAmerica branded products throughout the territory (Colorado).

On November 30, 2020, CannAmerica entered into a long-term licensing agreement for use of the Company's technology and processes with VIII Brands, LLC., a privately held company based in Colorado, with the intent of creating Consumer Packaged Goods (CPG's) in the United States.

VIII Brands is a hemp branding house started in 2019 for the purposes of introducing hemp-based cannabinoid CPG's into major retailers across the United States, where food, beverages, topicals and other consumption products are allowed.

Terms of the agreement include:

- The initial term will be for a period of 5 years;
- A licensing fee of US\$1,000,000 due 24 months after the effective date of the Agreement;
- Ongoing monthly fees for use of the Company's equipment to commence six months after the effective date of the Agreement;
- The Company is granted an option to purchase the Licensee;

Additionally, on December 10, 2020, the Company has entered into a license application agreement with GA Bioscience Research Inc. ("**GABRI**"), a Georgia company formed for the purpose of obtaining a Cannabis licensure in the State of Georgia (the "**License**"). The License will allow GABRI to conduct business operations for the cultivation and manufacture of legal cannabis products for medical use. CannAmerica will be assisting GABRI by providing the Company's expertise for the license application and, if the license application is successful, providing services for the design, build, installation of equipment and launching the operations.

Terms of the Agreement include:

- The initial term will be for the application window which will expire on December 28, 2020;
- Upon successful issuance of a License to GABRI, CannAmerica will provide expertise for the build-out of the project, equipment set-up, and training in all areas of cannabis cultivation, processing and manufacturing for a six-month term.
- The Agreement will be extended on a month-to-month basis until complete if the project continues past the six-month term; and
- The Company has a right of first refusal to enter into a separate licensing agreement with GABRI to bring the Company's branded products to the State of Georgia marketplace.

## **Expansion**

In addition to existing licensee relationships in the United States, the Company is continuously seeking opportunities to expand into new markets in the U.S. while also pursuing prospects for growth in Canada.

On August 8, 2019, CannAmerica entered into a long-term licensing agreement and brand partnership with Swiss Lux Products, Inc. Under the terms of agreement, Swiss Lux will have use of the Company's Intellectual Property, Branding, and Formulation processes in exchange for a royalty on all sales of the Company's products within Canada.

## **CannAmerica Brands Corp.**

### **Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

The terms of the Agreement include the following:

- the initial term of the Agreement will be for a period of 3 years;
- the Agreement provides for a license of the use of the Company's intellectual property, for which the Licensee will pay the Company a royalty percentage on gross sales;
- the Licensee will purchase all un-infused consumable ingredients, packaging supplies, and branded hardware as per the direction of the Company;
- the Licensee will follow formulations and processes provided by the Company;
- during the first 180 days of the initial term, the Licensee will employ one full-time salesperson in Canada to promote, market, advertise, and sell the products subject to the Agreement; and

Additionally, on January 27, 2021, the Company entered into a long-term agreement for exclusive licensing of CannAmerica Brand's technology and intellectual property for use in Canada (with [Leaf & Mark](#) (the "Licensee"), a cannabis edibles manufacturer operating out of a Health Canada licensed facility in Calgary, Alberta, in the (or - serving the) Canadian regulated market.

Terms of the Agreement include:

- An initial 5-year term;
- An exclusivity fee for access to the Company's proprietary technology and standard operating procedures and techniques;
- Ongoing support for the Licensee;
- An ongoing lease of the Company's proprietary equipment, for the term of the Agreement;
- Grants the Licensee the opportunity to automatically renew the lease at the end of term;
- A provision to increase the amount of technology for increased lease payments at the Licensee's request;
- Allows the Licensee the right to purchase proprietary substrate and ingredients from the Company;
- Grants the Licensee a six-month exclusivity option for use of the Company's technology and intellectual property within Europe, including the United Kingdom, which requires the Licensee to remit a deposit within 30 days of execution of an agreement in order to exercise that right, and;
- A provision for the Company to provide the Licensee with access to brands controlled by the Company upon request.

The Company is also exploring opportunities to launch new product lines with the goal of creating distinct revenue streams for all its branded products.

## **OUTLOOK**

Despite the current economic conditions, the Company continues to work on executing its strategy to grow as a market leader in the cannabis space and increase its presence in its existing markets along with infiltrating into new markets. This strategy is beginning to pay dividends, as in the past few months CannAmerica's diversification efforts include the aforementioned agreements signed with VIII Brands, LLC., GA Bioscience Research Inc. and Leaf & Mark.

In concert with expanding into new markets and obtaining more licensees, the Company is currently minimizing G&A expenses and emphasizing outstanding debts owed. In previous years, significant advertising and promotional costs were incurred by the Company prior to and after becoming publicly listed in order to promote the brand. Significant legal and professional fees were also incurred in order to establish licensing agreements in various states.

There was a decline in such spending during fiscal 2020 and management does not anticipate advertising or professional fees to revert back to prior year levels in the years ahead.

**CannAmerica Brands Corp.**

**Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

**RESULTS OF OPERATIONS**

Pursuant to the reverse takeover transaction described in the consolidated financial statements for the years ended March 31, 2020 and 2019 of CannAmerica, CannAmerica will report the operations of CannAmerica Holdings and its related historical comparatives as its continuing business.

**For the year ended March 31, 2021**

For the year ended March 31, 2021, the Company had a net loss of \$3,550,963 (2020: \$4,630,701). The variance between the comparative period is mainly due to a decrease in advertising, professional fees, and share based compensation expense.

The key highlights for the year include:

- License revenue of \$386,494 from licensees located in Colorado, Nevada, Oklahoma, and Massachusetts (2019: 915,096). Decline over prior year attributed to shortfall in the Nevada market due to economic conditions.
- License operations gross margin of \$328,415 versus \$783,092 in 2020. Decrease in gross margin over the prior year is attributed to the current economic conditions which has seen a decline in activity in licensee markets.
- Professional fees of \$249,082 (2020: \$528,143), which in the current year includes legal, accounting and consulting fees incurred in connection with ongoing operations and the amortization of fees incurred and paid for in 2018. Fees in the prior year include legal, accounting and consulting fees incurred in connection with the public listing, reverse takeover and business combination.
- Salaries and benefits of \$207,663 paid to the CEO, CCO, COO, and CFO, and operational staff as compared to \$713,701 in 2020. A portion of the variance from prior year is due to reversal of officer salary accruals.
- Share-based compensation of \$494,511 (2020: \$1,010,140) representing the fair value of options issued to certain directors of the Company.
- Interest and accretion expense of \$511,551 (2020: \$340,461) accrued on the outstanding promissory Notes Payable and Debentures.
- Advertising and promotion of \$303,556 (2020: \$747,772) associated with the Brands and licensing thereof.
- Non-cash impairment charge of Intangible assets of \$1,374,999 (2020: \$1,725,000) related to the DAFF Acquisition.

**CASH USED IN OPERATING ACTIVITIES**

For the year ended March 31, 2021, cash flows used in operating activities amounted to \$141,419 (2020: \$826,076). Cash flows resulted from a net loss of \$3,550,963 which were primarily offset by non-cash items and changes in non-cash working capital balances of \$3,409,544.

**CASH PROVIDED BY INVESTING ACTIVITIES**

For the year ended March 31, 2021, cash flows used in investing activities amounted to \$47,536 from the proceeds of the sale of investment less purchase of equipment. For the year ended March 31, 2020, cash flows used in investing activities amounted to \$20,649 for the purchase of equipment.

**CannAmerica Brands Corp.****Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

**CASH PROVIDED BY FINANCING ACTIVITIES**

For the year ended March 31, 2021, cash flows provided in financing activities amounted to \$89,389. Cash inflows of \$115,044 were related to a forgivable loan received from the Small Business Administration while outflows primarily resulted from the repayment of notes payable and debentures.

For the year ended March 31, 2020, cash flows provided in financing activities amounted to \$164,364. Cash inflows of \$558,840 were related to a non-brokered private placement of unsecured debentures while outflows primarily resulted from the repayment of notes payable and debentures.

**For the three months ended March 31, 2021**

For the three months ended March 31, 2021, the Company had a net loss of \$1,943,647.

The key highlights for the period include:

- License revenue of \$98,905 from licensees located in Colorado, Nevada, Oklahoma, and Massachusetts.
- Non-cash impairment charge of Intangible assets of \$1,374,999 related to the DAFF Acquisition.
- Professional fees of \$104,391, which in the current year includes legal, accounting and consulting fees incurred in connection with ongoing operations and the amortization of fees incurred and paid for in 2019.

**SELECTED QUARTERLY INFORMATION FOR MOST RECENT COMPLETED QUARTERS**

Pursuant to the reverse takeover transaction described above, CannAmerica will report the operations of CannAmerica Holdings and its related historical comparatives as its continuing business. CannAmerica Holdings was incorporated on December 11, 2017, and accordingly there are no quarterly results presented for periods prior to June 30, 2018.

|                                    | <b>March 31,<br/>2021</b> | <b>December 31,<br/>2020</b> | <b>September 30,<br/>2020</b> | <b>June 30,<br/>2020</b> |
|------------------------------------|---------------------------|------------------------------|-------------------------------|--------------------------|
|                                    | <b>\$</b>                 | <b>\$</b>                    | <b>\$</b>                     | <b>\$</b>                |
| Total revenue                      | 98,905                    | 141,894                      | 41,808                        | 103,887                  |
| Net loss                           | (1,943,647)               | (1,109,019)                  | (50,400)                      | (577,657)                |
| Basic and diluted income per share | (0.03)                    | (0.03)                       | (0.01)                        | (0.01)                   |

|                                    | <b>March 31,<br/>2020</b> | <b>December 31,<br/>2019</b> | <b>September 30,<br/>2019</b> | <b>June 30,<br/>2019</b> |
|------------------------------------|---------------------------|------------------------------|-------------------------------|--------------------------|
|                                    | <b>\$</b>                 | <b>\$</b>                    | <b>\$</b>                     | <b>\$</b>                |
| Total revenue                      | 121,502                   | 278,718                      | 249,326                       | 265,550                  |
| Net loss                           | (2,342,458)               | (433,558)                    | (1,038,386)                   | (816,299)                |
| Basic and diluted income per share | (0.02)                    | (0.02)                       | (0.02)                        | (0.01)                   |

**RELATED PARTY TRANSACTIONS**

All related party transactions have occurred in the normal course of operations. Related party transactions occur and are recorded at the exchange amounts agreed between the parties.

For the year ended March 31, 2021, the Company was charged \$82,592 in salaries (2020: \$145,417) by the CEO of the Company. At March 31, 2021 there is a balance of \$10,843 (2020: \$86,715) payable to the CEO.

## CannAmerica Brands Corp.

### Management's Discussion and Analysis for the Year Ended March 31, 2021

(All amounts expressed in CAD dollars, unless otherwise stated)

---

For the year ended March 31, 2021, the Company was charged \$103,840 in salaries by the COO of the Company. At March 31, 2021, there is a balance of \$7,720 (2020: \$nil) payable to the COO.

For the year ended March 31, 2021, the Company was charged \$34,823 in salaries (2020: \$145,417) by the CCO of the Company. At March 31, 2021, there is a balance of \$nil (2020: \$77,773) payable to the CCO.

For the year ended March 31, 2021, the Company was charged \$69,163 in management fees (2020: \$85,122) by the CFO of the Company. At March 31, 2021, there is a balance of \$6,288 (2020: \$14,187) payable to the CFO.

For the year ended March 31, 2021, the Company recorded sales of \$39,825 (2020: \$nil) to a company under common control. At March 31, 2021, there is a balance of \$35,865 (2020: \$nil) receivable from this company.

#### Key management personnel compensation

Key management is comprised of the Company's directors and executive officers. The Company incurred the following key management compensation charges during the years ended March 31, 2021 and 2020:

|                                      | 2021           | 2020             |
|--------------------------------------|----------------|------------------|
|                                      | \$             | \$               |
| Salaries, bonuses, fees and benefits | 290,418        | 437,614          |
| Share based compensation             | 401,011        | 636,500          |
|                                      | <b>691,429</b> | <b>1,074,114</b> |

#### OUTSTANDING SHARE DATA

The Company has an unlimited number of common shares without par value authorized for issuance.

As at October 5, 2021, the Company had 70,386,855 common shares issued and outstanding.

As at October 5, 2021, the Company had a total of 5,400,000 options and 4,411,765 warrants outstanding.

#### FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The classification and measurement of financial assets is based on the Company's business models for managing its financial assets and whether the contractual cash flows represent solely payments of principal and interest ("SPPI"). Financial assets are initially measured at fair value plus, in the case of financial assets not at fair value through profit and loss ("FVTPL") transaction costs.

Financial assets are subsequently measured at either:

- i. amortized cost;
- ii. fair value through other comprehensive income ("FVTOCI"); or
- iii. at fair value through profit or loss ("FVTPL").

Financial liabilities are generally classified and measured at fair value at initial recognition and subsequently measured at amortized cost.

**CannAmerica Brands Corp.****Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

The following table summarizes the classification of the Company's financial instruments:

| <b>Financial assets</b>      |                |
|------------------------------|----------------|
| Cash                         | FVTPL          |
| Accounts receivable          | Amortized cost |
| Investment in licensee       | FVTPL          |
| <b>Financial liabilities</b> |                |
| Accounts payable             | Amortized cost |
| Notes payable                | Amortized cost |
| Debentures                   | Amortized cost |

**Credit risk**

Credit risk arises from cash held with banks and financial institutions, as well as credit exposure on outstanding accounts receivables. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The Company seeks to limit its exposure to this risk by holding its cash in reputable financial institutions. The Company does not have significant credit risk with respect to customers.

**Liquidity risk**

The following table details the Company's expected remaining contractual cash flow requirements for its financial liabilities on repayment or maturity periods. The amounts presented are based on the contractual undiscounted cash flows and may not agree with the carrying amounts in the consolidated statements of financial position:

| <b>As at March 31, 2021</b> | <b>Up to 1 year</b> | <b>1 - 5 years</b> | <b>Total</b> |
|-----------------------------|---------------------|--------------------|--------------|
| Accounts payable            | 297,169             | -                  | 297,169      |
| Notes payable               | 3,846,128           | -                  | 3,846,128    |
| Loan payable                | 115,044             | -                  | 115,044      |
| Debentures                  | 467,545             | -                  | 467,545      |
|                             | 4,725,886           | -                  | 4,725,886    |

The Company expected to repay the notes payable with proceeds from a private placement financing prior to the maturity date and is continuing to pursue financing. If the Company is unsuccessful with the financing, or unable to otherwise repay the notes payable the note holders could foreclose on the collateral.

**Currency risk**

Currency risk is the risk that changes in foreign exchange rates will affect the Company's income or the value of its holdings of financial instruments. The functional currency of DAFF is the US Dollar and the majority of transactions are transacted in the US Dollar. In addition, all DAFF financial liabilities are denominated in the US Dollar. The Company does not undertake currency hedging activities to mitigate its foreign currency risk. The impact on the Company's profit or loss resulting from a 10% fluctuation in foreign exchange rates would be approximately \$27,000 (2020: \$56,000).

**Interest rate risk**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market interest rates. The Company has debt instruments however the interest rate is fixed and therefore the related interest rate risk is minimal.

**Capital management**

The Company's objectives when managing its capital are to safeguard its ability to continue as a going concern, to meet its capital expenditures for its continued operations, and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. The Company manages its capital structure and adjusts it in light of

**CannAmerica Brands Corp.**

**Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares, enter into debt facilities, or acquire or dispose of assets. The Company is not subject to externally imposed capital requirements.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company's capital management approach in the period. The Company considers its shareholders' equity as capital.

**COMMITMENTS**

The Company does not have any commitments for capital expenditures as at March 31, 2021.

**OFF-BALANCE SHEET ARRANGEMENTS AND PROPOSED TRANSACTIONS**

The Company has no off-balance sheet arrangements.

**SIGNIFICANT ACCOUNTING POLICIES**

The Company follows the significant accounting policies as described in Note 2 of the consolidated financial statements for the year ended March 31, 2021, and accompanying notes thereto for CannAmerica, CannAmerica Holdings, and DAFF.

**CRITICAL ACCOUNTING POLICIES AND ESTIMATES**

The Company has prepared the consolidated financial statements in accordance with IFRS. Significant accounting policies are described in Note 2 of the Company's financial statements for the years ended March 31, 2021 and 2020.

The preparation of financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates.

The Company's significant estimates and judgements for the year ended March 31, 2021 included:

Significant accounting estimates

- i. the measurement of deferred income tax assets and liabilities;
- ii. inputs used in impairment calculations; and
- iii. inputs used in share-based compensation

Significant accounting judgments

- i. the evaluation of the Company's ability to continue as a going concern;
- ii. assessment of indications of impairment; and
- iii. assessment of whether an acquisition is a business combination or an asset acquisition

**Accounting standards and amendments issued but not yet effective**

Accounting standards or amendments to existing accounting standards that have been issued but have future effective dates are either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements.

**CannAmerica Brands Corp.**

**Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

**RISKS AND UNCERTAINTIES**

**Conflicts of Interest**

Certain directors of the Company also serve as directors and/or officers of other companies involved in other business ventures. Consequently, there exists the possibility for such directors to be in a position of conflict. Any decision made by such directors involving the Company will be made in accordance with their duties and obligations to deal fairly and in good faith with the Company and such other companies. In addition, such directors will declare, and refrain from voting on, any matter in which such directors may have a conflict of interest.

**Negative Operating Cash Flows**

As the Company is at the early stage start up stage it may continue to have negative operating cash flows. Prior to the development of existing revenue streams from its business, the Company may continue to have negative operating cash flows until it can realize stable cash flow from operations.

**Risks Related as a Going Concern**

The Company commenced earning revenue in April 2018 and has a limited history. No assurance can be provided that historical performance will be indicative of future performance. The ability of the Company to continue as a going concern is dependent upon its ability to achieve profitable operations, obtain additional capital and receive continued support from its shareholders.

**Reliance on Key Personnel and Advisors**

The Company relies heavily on its officers. The loss of their services may have a material adverse effect on the business of the Company. There can be no assurance that one or all of the employees of, and contractors engaged by, the Company will continue in the employ of, or in a consulting capacity to, the Company or that they will not set up competing businesses or accept positions with competitors. There is no guarantee that certain employees of, and contractors to, the Company who have access to confidential information will not disclose the confidential information.

**Difficulty to Forecast**

The Company will need to rely largely on its own market research to forecast industry trends and statistics as detailed forecasts are, with certain exceptions, not generally available from other sources at this early stage of the cannabis industry. A failure in the demand for the Company's products to materialize as a result of competition, technological change, change in the regulatory or legal landscape or other factors could have a material adverse effect the Company's business, financial condition and results of operations.

**Impact of COVID-19**

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. Management continues to monitor the situation and is assessing the impact on the Company.

**MANAGEMENT'S RESPONSIBILITY FOR THE FINANCIAL STATEMENTS**

The information provided in this report is the responsibility of management. In the preparation of these statements, estimates are sometimes necessary to make a determination of future values for certain assets or liabilities. Management believes such estimates have been based on careful judgments and have been properly reflected in the accompanying financial statements.

**RISK FACTORS**

**Market Risk for Securities**

The market price for the Company's common shares is subject to fluctuations. Factors such as commodity prices, government regulation, interest rates, share price movements of peer companies and competitors, as well as overall market movements, may have a significant impact on the market price securities. The stock market has from time to

## **CannAmerica Brands Corp.**

### **Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

time experienced extreme price and volume fluctuations, which have often been unrelated to the operating performance of particular companies.

#### **Uninsured or Uninsurable Risk**

The Company may become subject to liability for risks against which cannot be insured or against which the Company may elect not to insure due to the high cost of insurance premiums or other factors. The payment of any such liabilities would reduce the funds available for usual business activities. Payment of liabilities for which insurance is not carried may have a material adverse effect on the Company's financial position and operations.

#### **Key Personnel Risk**

The Company's success will depend on its directors and officers to develop the business, manage operations, attract and retain key quality staff and consultants. The loss of any key person or the inability to find and retain new key persons could have a material adverse effect on the business. No assurance can be provided that the Company will be able to attract or retain key personnel in the future, which may adversely impact operations.

#### **Dividend Risk**

The Company has not paid dividends in the past and does not anticipate paying dividends in the near future. Earnings are expected to be retained to finance further growth and, when appropriate, retire obligations.

#### **Share Price Volatility Risk**

External factors outside of the Company's control such as sentiments toward the cannabis sector may have a significant impact on the market price of the Company's common shares. Global stock markets, including the CSX Exchange, have from time to time experienced extreme price and volume fluctuations that have often been unrelated to the operations of particular companies. There can be no assurance that an active or liquid market will develop or be sustained for the common shares.

#### **Some of the Company's planned business activities, while believed to be compliant with certain applicable U.S. state and local laws, are illegal under United States federal law.**

Cannabis is illegal under federal U.S. law. Unlike in Canada which has federal legislation uniformly governing the cultivation, distribution, sale and possession of Medical Cannabis under the Access to Cannabis for Medical Purposes Regulations, investors are cautioned that in the United States, marijuana is largely regulated at the state level. Although certain states and territories of the U.S. authorize medical or recreational cannabis production and distribution by licensed or registered entities, under U.S. federal law, the possession, use, cultivation, and transfer of cannabis and any related drug paraphernalia is illegal and any such acts are criminal acts under federal law under any and all circumstances under the U.S. Controlled Substances Act. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and in case of conflict between federal and state law, the federal law must be applied. An investor's contribution to and involvement in such activities may result in federal civil and/or criminal prosecution, including forfeiture of his, her or its entire investment.

Violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including but not limited to disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, its holding (directly or indirectly) of marijuana licenses in the United States, the listing of its securities on various stock exchanges, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial.

In addition, since the possession and use of cannabis and any related drug paraphernalia is illegal under U.S. federal law, the Company may be deemed to be aiding and abetting illegal activities through the contracts it has entered into and the products that it intends to provide. As a result, U.S. law enforcement authorities, in their attempt to regulate the

**CannAmerica Brands Corp.**

**Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

illegal use of cannabis and any related drug paraphernalia, may seek to bring an action or actions against the Company, including, but not limited to, aiding and abetting another's criminal activities. The Federal aiding and abetting statute provide that anyone who "commits an offense against the United States or aids, abets, counsels, commands, induces or procures its commission, is punishable as a principal." As a result of such an action, the Company may be forced to cease operations and its investors could lose their entire investment. Such an action would have a material negative effect on the Company's business and operations.

**The Company's investments and operations in the United States may be subject to heightened scrutiny.**

For the reasons set forth above, the Company's existing investments and operations in the United States, and any future investments or operations, may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada. As a result, the Company may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on the Company's ability to invest in the United States or any other jurisdiction. It has also been reported by certain publications (the "Publications") in Canada that The Canadian Depository for Securities Limited is considering a policy shift that would see its subsidiary, CDS Clearing and Depository Services Inc. ("CDS"), refuse to settle trades for cannabis issuers that have investments in the United States. CDS is Canada's central securities depository, clearing and settlement hub settling trades in the Canadian equity, fixed income and money markets. On February 8, 2018, CDS signed the CDS Memorandum of Understanding (the "CDS MOU") with the Aequitas NEO Exchange Inc., the CSE, the Toronto Stock Exchange and the TSX Venture Exchange (collectively, the "Exchanges"). The CDS MOU outlines CDS' and the Exchanges' understanding of Canada's regulatory framework applicable to the rules and procedures and regulatory oversight of the Exchanges and CDS. The CDS MOU confirms, with respect to the clearing of listed securities, that CDS relies on the Exchanges to review the conduct of listed issuers. As a result, there currently is no CDS ban on the clearing of securities of issuers with marijuana-related activities in the United States. However, if CDS were to proceed in the manner suggested by these publications, and apply such a policy to the Company, it would have a material adverse effect on the ability of Common Shares to make trades. In particular, the Common Shares would become highly illiquid as investors would have no ability to affect a trade of Common Shares through the facilities of a stock exchange.

Government policy changes or public opinion may also result in a significant influence over the regulation of the cannabis industry in Canada, the United States or elsewhere. A negative shift in the public's perception of Medical or Recreational Cannabis in the United States or any other applicable jurisdiction could affect future legislation or regulation. Among other things, such a shift could cause state jurisdictions to abandon initiatives or proposals to legalize medical and/or Recreational Cannabis, thereby limiting the number of new state jurisdictions into which the Company could expand. Any inability to fully implement the Company's expansion strategy may have a material adverse effect on the Company's business, financial condition and results of operations.

**There is uncertainty surrounding the Trump Administration and its influence and policies in opposition to the cannabis industry as a whole.**

There continues to be uncertainty as to the position the United States and the Trump Administration will take with respect to cannabis and the federal government's enforcement of federal law in relation to cannabis. Implementation by the U.S. of new legislative or regulatory regimes could impose additional costs on the Company, decrease U.S. demand for the Company's services or otherwise negatively impact the Company, which may have a material adverse effect on the Company's business, financial condition and operations.

On January 4, 2018 the Cole Memorandum was rescinded by Former Attorney General Jeff Sessions. While this did not create a change in federal law, as the Cole Memorandum was not itself law, the revocation removed the Department of Justice's guidance to U.S. attorneys that state-regulated cannabis industries substantively in compliance with the Cole Memorandum's guidelines should not be a prosecutorial priority.

Former Attorney General Jeff Sessions also issued a one-page memorandum known as the "Sessions Memorandum." This confirmed the rescission of the Cole Memorandum and explained that the Cole Memorandum was "unnecessary" due to existing general enforcement guidance as set forth in the U.S. Attorney's Manual. The U.S. Attorney's Manual enforcement priorities, like those of the Cole Memorandum, are also based on the federal government's limited resources, and include "law enforcement priorities set by the Attorney General," the "seriousness" of the alleged crimes,

**CannAmerica Brands Corp.**

**Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

the "deterrent effect of criminal prosecution," and "the cumulative impact of particular crimes on the community." The Sessions Memorandum emphasizes that marijuana is a Schedule I controlled substance and states the statutory view that it is a "dangerous drug and that marijuana activity is a serious crime."

**The approach to the enforcement of cannabis laws in the U.S. may be subject to change or may not proceed as previously outlined.**

The Cole Memorandum outlined certain priorities for the Department of Justice relating to the prosecution of cannabis offenses. In particular, the Cole Memorandum noted that in jurisdictions that have enacted laws legalizing cannabis in some form and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of cannabis, conduct in compliance with those laws and regulations is less likely to be a priority at the federal level. Notably, however, the Department of Justice has never provided specific guidelines for what regulatory and enforcement systems it deems sufficient under the Cole Memorandum standard.

However, as noted above, on January 4, 2018 the Cole Memorandum was revoked by Former Attorney General Jeff Sessions. Given this revocation, the Department of Justice under the Trump Administration or an aggressive U.S. federal prosecutor could allege that the Company, its board of directors, and officers, "aided and abetted" or otherwise involved themselves in violations of federal law. Under these circumstances, it is possible that the federal prosecutor would seek to seize the assets of the Company, and to recover the "illicit profits" previously distributed to shareholders resulting from any of the foregoing financing or services. In these circumstances, the Company's operations would cease, shareholders may lose their entire investment and directors, officers and/or shareholders may be left to defend any criminal charges against them at their own expense and, if convicted, be sent to federal prison.

**Regulatory scrutiny of the Company's industry may negatively impact its ability to raise additional capital.**

The Company's business activities rely on newly established and/or developing laws and regulations in various states in the United States. These laws and regulations are rapidly evolving and subject to change with minimal notice. Regulatory changes may adversely affect the Company's profitability or cause it to cease operations entirely. The cannabis industry may come under the scrutiny or further scrutiny by the U.S. Food and Drug Administration, Securities and Exchange Commission, the Department of Justice ("DOJ"), the Financial Industry Regulatory Advisory or other federal, Washington State or other applicable state or non-governmental regulatory authorities or self-regulatory organizations that supervise or regulate the production, distribution, sale or use of cannabis for medical or nonmedical purposes in the United States. It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any proposals will become law. The regulatory uncertainty surrounding the cannabis industry may adversely affect the business and operations of the Company, including without limitation, the costs to remain compliant with applicable laws and the impairment of its ability to raise additional capital, which could reduce, delay or eliminate any return on investment in the Company.

**The Company may have difficulty accessing the service of banks and processing credit card payments in the future, which may make it difficult for the Company to operate.**

In February 2014, the Financial Crimes Enforcement Network ("FinCEN") bureau of the U.S. Treasury Department issued guidance (which is not law) with respect to financial institutions providing banking services to cannabis business, including burdensome due diligence expectations and reporting requirements. This guidance does not provide any safe harbors or legal defenses from examination or regulatory or criminal enforcement actions by the DOJ, FinCEN or other federal regulators. Thus, most banks and other financial institutions do not appear to be comfortable providing banking services to cannabis-related businesses, or relying on this guidance, which can be amended or revoked at any time by the Trump Administration. In addition to the foregoing, banks may refuse to process debit card payments and credit card companies generally refuse to process credit card payments for cannabis-related businesses. As a result, the Company may have limited or no access to banking or other financial services in the United States and may have to operate the Company's U.S. business on an all-cash basis. The inability or limitation in the Company's ability to open or maintain bank accounts, obtain other banking services and/or accept credit card and debit card payments may make it difficult for the Company to operate and conduct its business as planned. The Company is actively pursuing alternatives that ensure its operations will continue to be compliant with the FinCEN guidance and existing disclosures around cash management and reporting to the IRS once it moves from development into production.

## **CannAmerica Brands Corp.**

### **Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

#### **U.S. Federal trademark and patent protection may not be available for the intellectual property of the Company due to the current classification of cannabis as a Schedule I controlled substance.**

As long as cannabis remains illegal under U.S. federal law as a Schedule I controlled substance pursuant to the CSA, the benefit of certain federal laws and protections which may be available to most businesses, such as federal trademark and patent protection regarding the intellectual property of a business, may not be available to the Company. As a result, the Company's intellectual property may never be adequately or sufficiently protected against the use or misappropriation by third parties. In addition, since the regulatory framework of the cannabis industry is in a constant state of flux, the Company can provide no assurance that it will ever obtain any protection of its intellectual property, whether on a federal, state or local level.

#### **The Company's and its Licensees' contracts may not be legally enforceable in the United States.**

Because the Company's contracts involve cannabis and other activities that are not legal under U.S. federal law and in some jurisdictions, the Company and the Licensees may face difficulties in enforcing their contracts in U.S. federal and certain state courts.

#### **It may be difficult, if not impossible, for U.S. holders of the Company's securities to resell them over the CSE.**

It has recently come to management's attention that all major securities clearing firms in the U.S. have ceased participating in transactions related to securities of Canadian public companies involved in the medical marijuana industry. This appears to be due to the fact that marijuana continues to be listed as a controlled substance under U.S. federal law, with the result that marijuana-related practices or activities, including the cultivation, possession or distribution of marijuana, are illegal under U.S. federal law. However, management understands that the action by U.S. securities clearing firms also extends to securities of companies that carry on business operations entirely outside the U.S. Accordingly, U.S. residents who acquire securities of the Company may find it difficult – if not impossible – to resell such securities over the facilities of any Canadian stock exchange on which the shares may then be listed. It remains unclear what impact, if any, this and any future actions among market participants in the U.S. will have on the ability of U.S. residents to resell any securities of the Company that they may acquire in open market transactions.

#### **Canadian Investors in the Company's Securities and the Company's directors, officers and employees may be subject to travel and entry bans into the United States.**

News media have reported that United States immigration authorities have increased scrutiny of Canadian citizens who are crossing the United States–Canada border with respect to persons involved in cannabis businesses in the United States. There have been a number of Canadians barred from entering the United States as a result of an investment in or act related to United States cannabis businesses. In some cases, entry has been barred for extended periods of time.

The majority of persons travelling across the Canadian and U.S. border do so without incident. Some persons are simply barred entry one time. The U.S. Department of State and the Department of Homeland Security has indicated that the United States has not changed admission requirements in response to the pending legalization in Canada of recreational cannabis, but anecdotal evidence indicates that the United States may be increasing enforcement of its federal laws regarding marijuana-related practices or activities, including the cultivation, possession or distribution of marijuana.

Admissibility to the United States may be denied to any person working or 'having involvement in' the marijuana industry, including in States where it is deemed legal, according to United States Customs and Border Protection. Additionally, legal experts have indicated that if the admission criteria are applied broadly, this may result in a determination that the act of investing, working or collaborating with a U.S. cannabis company is considered trafficking in a Schedule I controlled substance or aiding, abetting, assisting, conspiring or colluding in the trafficking of a Schedule I controlled substance. Inadmissibility in the United States implies a lifetime ban for entry as such designation is not lifted unless an individual applies for and obtains a waiver.

Company directors, officers or employees traveling from Canada to the United States for the benefit of the Company may encounter enhanced scrutiny by United States immigration authorities that may result in the employee not being permitted to enter the United States for a specified period of time. If this happens to Company directors, officers or employees, then this may reduce our ability to manage our business effectively in the United States.

**Due to the classification of cannabis as a Schedule I controlled substance under the CSA, banks and other financial institutions which service the cannabis industry are at risk of violating certain financial laws, including anti-money laundering statutes.**

Because the manufacture, distribution, and dispensation of cannabis remains illegal under the CSA, banks and other financial institutions providing services to cannabis-related businesses risk violation of federal anti-money laundering statutes (18 U.S.C. §§ 1956 and 1957), the unlicensed money-remitter statute (18 U.S.C. § 1960) and the U.S. Bank Secrecy Act. These statutes can impose criminal liability for engaging in certain financial and monetary transactions with the proceeds of a "specified unlawful activity" such as distributing controlled substances which are illegal under federal law, including cannabis, and for failing to identify or report financial transactions that involve the proceeds of cannabis-related violations of the CSA. The Company may also be exposed to the foregoing risks. In the event that any of the Company's investments, or any proceeds thereof, any dividends or distributions therefrom, or any profits or revenues accruing from such investments in the United States were found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under one or more of the statutes noted above or any other applicable legislation. This could restrict or otherwise jeopardize the ability of the Company to declare or pay dividends, effect other distributions or subsequently repatriate such funds back to Canada. In the foreseeable future, in the event that a determination was made that any such investments in the United States could reasonably be shown to constitute proceeds of crime, the Company may decide or be required to suspend declaring or paying dividends without advance notice and for an indefinite period of time.

**State and local laws and regulations may heavily regulate brands and forms of cannabis products and there is no guarantee that the Company's proposed products and brands will be approved for sale and distribution in any state.**

States only allow the manufacture, sale and distribution of cannabis products that are grown in that state and may require advance approval of such products. Certain states and local jurisdictions have promulgated certain requirements for approved cannabis products based on the form of the product and the concentration of the various cannabinoids in the product. There is no guarantee that the Company's products will be approved to the extent necessary. If the products are approved, there is a risk that any state or local jurisdiction may revoke its approval for such products based on changes in laws or regulations or based on its discretion or otherwise.

**Lack of Access to United States Bankruptcy Protections.**

Because cannabis is a Schedule I substance under the CSA, many courts have denied cannabis businesses federal bankruptcy protections, making it difficult for lenders to be made whole on their investments in the cannabis industry in the event of a bankruptcy. If the Company or one of its Licensees were to experience a bankruptcy, there is no guarantee that United States federal bankruptcy protections would be available to the Company or its Licensee, which would have a material adverse effect.

**The failure of the Licensees to fulfill their financial obligations with respect to royalty payments under their license agreements or to otherwise adequately produce, market and sell products bearing the Company's brand names in their respective license categories could have a material adverse effect on the Company's business, financial condition and results of operations.**

The Company's revenues are almost entirely dependent on royalty payments made to the Company pursuant to license agreements entered into with licensees of the Company's brands. The failure of the Licensees to satisfy their financial obligations under these agreements, or their inability to operate successfully or at all, could result in a breach of an agreement, early termination of an agreement or non-renewal of an agreement. A decrease or elimination of revenue could have a material adverse effect on the Company's financial condition, results of operation and cash flows.

During the term of a license agreement, the Company's revenues and the value of the Company's brands substantially depend upon the Licensee's ability to maintain the quality and marketability and market acceptance of the branded products licensed to such licensee and their failure to do so could negatively affect consumer perception of the Company's brands and harm the Company's future growth and prospects. Further, the failure of the Licensees to meet their production, manufacturing and distribution requirements, or a weak economy or softness in the cannabis space

## **CannAmerica Brands Corp.**

### **Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

could cause the Licensees to default on their obligations. In addition, the Licensees' inability to maintain market acceptance of the Company's brands or the Company's failure to monitor the Licensees' compliance with their license agreements or take appropriate corrective action when necessary may subject the Company's intellectual property assets to cancellation, loss of rights or devaluation and any devaluation of the Company's intellectual property could cause a material impairment in the carrying value of such intellectual property, potentially resulting in a charge as an expense to the Company's results of operations. If such developments occur or the Licensees are otherwise not successful, the value and recognition of the Company's brands, as well as the Company's business, financial condition and results of operations, could be materially adversely affected.

#### **The Company's business depends on continued market acceptance of the Company's brands and the products bearing these brands.**

The cannabis space is highly susceptible to changes in consumer preferences and continued market acceptance of the Company's brands and the Licensees' products, as well as market acceptance of any future products bearing the Company's brands and is subject to a high degree of uncertainty. In order to generate revenues and profits, the Licensees must continually develop product offerings that appeal to consumers. Generally, the Company does not retain the rights to monitor the products that the Licensee's design and produce with the exception of the brands licensed by the Company and can provide no assurance that licensees will develop, market and sell other products and brands that appeal to consumers. Any significant changes in consumer preferences or any inability on the Licensees' part to anticipate or react to such changes could reduce demand for the Company's branded products and erode the competitiveness of such products, which would negatively affect the Company's financial condition, results of operations and cash flows.

The continued success of the Company's brands and branded products and market acceptance of new products and product categories are also dependent on the Company's ability to continually improve the effectiveness of the Company's marketing efforts. The Company devotes significant resources and expenditures to promoting the Company's brands and new product launches, but there can be no assurance as to the Company's continued ability to effectively execute the Company's marketing programs. To the extent the Licensees misjudge the market for the Company's brands and branded products, or the Company's marketing efforts are unsuccessful, the Company's business, results of operations and prospects will be adversely affected.

#### **The Company has incurred a substantial amount of indebtedness in connection with the Company's acquisition, which could adversely affect the Company's financial condition and results of operations.**

The financial statements for the Company disclose notes payable. These notes are due 13 months after the date the Company becomes a reporting issuer. There is no assurance that the business will generate sufficient operating cash flow to repay the debt or that the Company will be successful in obtaining future financing.

The Company's high level of indebtedness increases the possibility that the Company may be unable to generate cash sufficient to pay when due the principal of, interest on or other amounts due in respect of such indebtedness. In addition, the Company may incur additional debt from time to time to finance strategic acquisitions, investments, joint ventures or for other purposes, subject to the restrictions contained in the documents that govern the Company's indebtedness. If the Company incurs additional debt, the risks associated with the Company's leverage, including the Company's ability to service debt, would increase.

The Company's increased level of indebtedness could have other important consequences, which include, but are not limited to, the following:

- a substantial portion of the Company's cash flow from operations could be required to pay principal and interest on the Company's debt;
- the Company's leverage could increase the Company's vulnerability to general economic downturns and adverse competitive and industry conditions, placing the Company at a disadvantage compared to those of the Company's competitors that are less leveraged;
- the Company's debt service obligations could limit the Company's flexibility in planning for, or reacting to, changes in the Company's business and in the brand licensing industry;

**CannAmerica Brands Corp.**

**Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

- the Company's failure to comply with the restrictive covenants in the documents governing the Company's indebtedness could result in an event of default that, if not cured or waived, results in foreclosure on substantially all of the Company's assets; and
- the Company's level of debt may restrict the Company from raising additional financing on satisfactory terms to fund strategic acquisitions, investments, joint ventures and other general corporate requirements.

The Company cannot be certain that its earnings will be sufficient to allow the Company to pay principal and interest on its debt and meet its other obligations. If the Company does not have sufficient earnings, it may be required to seek to refinance all or part of the Company's then existing debt, sell assets, make additional borrowings or sell more securities, none of which the Company can guarantee that it will be able to do.

**The Company may require additional capital to finance the acquisition of additional brands, and the Company's inability to raise such capital on beneficial terms or at all could limit the Company's growth.**

The Company may, in the future, require additional capital to help fund all or part of potential acquisitions. If, at the time required, the Company does not have sufficient cash to finance those additional capital needs, the Company will need to raise additional funds through equity and/or debt financing. The Company cannot guarantee that, if and when needed, additional financing will be available to the Company on acceptable terms or at all. If additional capital is needed and is either unavailable or cost prohibitive, the Company's growth may be limited as the Company may need to change the Company's business strategy to slow the rate of, or eliminate, the Company's expansion plans. In addition, any additional financing the Company undertakes could impose additional covenants upon the Company that restrict the Company's operating flexibility, and, if the Company issues equity securities to raise capital, the Company's existing stockholders may experience dilution or the new securities may have rights senior to those of the Company's common stock.

**The Company or the Licensees may not be able to continue to compete successfully because of intense competition within the Licensees' markets, the strength of some of their competitors or other factors.**

The Company's licenses are for products primarily in the cannabis markets, in which the Licensees face intense competition. Competitive factors in these markets include quality, price, name recognition, service and advertising. Changing customer preferences and the limited availability of shelf space in dispensaries could materially and adversely affect the competitive position of the Licensees' products. Many of the Licensees' competitors have greater financial, distribution, marketing and other resources than the Licensees and have achieved significant name recognition for their brands. The Licensees may be unable to successfully compete in the markets for their products, which would adversely affect the Company's revenues and cash flows, and the Company may not be able to continue to compete successfully with respect to the Company's licensing arrangements.

**The Company may not be able to adequately protect the Company's intellectual property rights, which could compromise its competitive position and decrease the value of the Company's brands.**

The loss of or inability to enforce the Company's proprietary rights of its intellectual property could materially and adversely affect the Company's business and financial condition. For instance, if any third party independently develops similar products to those marketed and distributed by the Licensees or manufactures knock-offs of such products, it may harm the reputation of the Company's brands, decrease their value or cause a decline in the Licensees' sales and thus the Company's revenues.

The Company may need to bring legal claims to enforce or protect the Company's intellectual property rights. Any litigation, whether successful or unsuccessful, could result in substantial costs and diversions of resources and negatively impact the Company's business operations. In addition, notwithstanding the rights the Company have secured in the Company's intellectual property, third parties may bring claims against the Company or the Licensees alleging that the Company or the Licensees have infringed on their intellectual property rights or that the Company or the Licensees' intellectual property rights are not valid. Any claims against the Company or the Licensees, with or without merit, could be time consuming and costly to defend or litigate and therefore could adversely affect the Company's business. In addition, to the extent that any of the Company's intellectual property assets is deemed to violate the proprietary rights of third parties in any litigation or proceeding or as a result of any claim, then the Company or the Licensees may be prevented from using it, which could cause a breach or termination of license agreements. If the

**CannAmerica Brands Corp.**

**Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

Licensees are prevented from using the intellectual property that the Company has licensed to them, the revenues of the Licensees will be reduced with respect to those intellectual property assets, and the related royalty payments the Company receives could be reduced. Litigation with respect to the Company's intellectual property or breaches of the Company's license agreements could result in a judgment or monetary damages.

**The Company depends upon the services of the Company's key executives, including the Company's Chief Executive Officer, Mr. Dan Anglin. If the Company loses the services of Mr. Anglin or other key executives, the Company may not be able to fully implement the Company's business plan and future growth strategy, which would harm the Company's business and prospects.**

The Company's success is largely dependent upon the expertise and knowledge of the Company's Chief Executive Officer, Mr. Dan Anglin, and other key members of the executive team, whom the Company relies upon to formulate the Company's business strategies. The Company's key executive's leadership and experience in the cannabis industry are essential to the successful implementation of the Company's business and marketing strategy. The Company does not carry key person life insurance covering the Company's key executives. The loss of the services of the Company's key executives could have a material adverse effect on the Company's business prospects, financial condition, results of operations and cash flows.

**The Company's results of operations may fluctuate significantly, which makes it difficult to predict the Company's performance and could result in volatility in the Company's stock price.**

The Company may experience variations in its revenue and results of operations from quarter to quarter. This variability is affected by numerous factors, including:

- the timing of the introduction of new licensed products by the Licensees;
- the level of consumer acceptance of the Company's brands and licensed products;
- general economic and industry conditions in the cannabis space;
- the availability of viable licensees that meet the Company's brand criteria; and
- the timing and amount of marketing and other expenditures.

Because of these fluctuations in the Company's revenues, operating expenses and cash flows, it could be difficult to make period-to-period comparisons of the Company's result of operations and liquidity and it may be difficult for securities analysts and investors to predict the Company's performance. As a result, the Company's results of operations in any particular quarter may be below the expectations of securities analysts or investors. Fluctuations in the Company's performance and the failure to meet analyst expectations could cause declines or volatility in the Company's stock price.

**The Company does not foresee paying dividends in the foreseeable future.**

The Company has not paid dividends and does not anticipate paying dividends in the foreseeable future. Instead, the Company plans to retain any earnings to maintain and expand existing licensing operations, further develop the Company's brands and finance the acquisition of additional assets and search for new opportunities.

**The Company has a significant amount of intangible assets, including the Company's trademarks, recorded on the Company's balance sheet.**

If there are changes in market conditions and declines in the estimated fair value of these assets, the Company may have to write-down intangible assets and may be required to record impairments of the Company's intangible assets in the future which could adversely affect the Company's results of operations.

**The Company's business, financial condition and results of operations could suffer in the event of security breaches, cyber-attacks or unauthorized disclosures of personal information.**

In conducting their businesses, including their e-commerce businesses, the Licensees and retail partners obtain and transmit confidential information about their customers, including credit card and other personal information, through their websites and their information technology systems. To the best of the Company's knowledge, the Licensees have

## **CannAmerica Brands Corp.**

### **Management's Discussion and Analysis for the Year Ended March 31, 2021**

(All amounts expressed in CAD dollars, unless otherwise stated)

---

not experienced any material misappropriation, loss or other unauthorized disclosure of confidential or personally identifiable information as a result of a security breach or cyber-attack. If the Licensees experience such a security breach or cyber-attack, it could adversely affect their business and operations, including damaging their reputation and their relationships with their customers, exposing them to risks of litigation and liability. There can be no assurance that the Licensees will not experience any future security breaches, cyber-attacks or unauthorized disclosures. The Licensees may incur significant costs to comply with laws regarding the protection and unauthorized disclosure of personal information, which could also negatively affect their ability to generate sales and make royalty payments to the Company, resulting in a material adverse effect on its business, financial condition and results of operations.

#### **The size of the Company's target market is difficult to quantify, and investors will be reliant on their own estimates on the accuracy of market data.**

Because the cannabis industry is in an early stage with uncertain boundaries, there is a lack of information about comparable companies available for potential investors to review in deciding about whether to invest in the Company and, few, if any, established companies whose business model the Company can follow or upon whose success the Company can build. Accordingly, investors will have to rely on their own estimates in deciding about whether to invest in the Company. There can be no assurance that the Company's estimates are accurate or that the market size is sufficiently large for its business to grow as projected, which may negatively impact its financial results. The Company regularly purchases and follows market research.

#### **CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This MD&A contains certain statements that may constitute "forward-looking statements". Forward-looking statements include but are not limited to, statements regarding future expansion, business goals, anticipated business developments and the timing thereof, regulatory compliance, sufficiency of working capital, business and financing plans, and other forward-looking statements including but not limited to information concerning intentions, plans and future actions of the Company.

In connection with the forward-looking information contained in this MD&A, the Company has made assumptions about the Company's ability to expand operations, acquire assets and/or businesses and new brands, the profitability of its licensed brands, and its ability to operate in the future without any regulation or law imposed which would prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company's normal course of business.

The forward-looking information in this MD&A reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or which by their nature refer to future events. The Company cautions that any forward-looking statements by the Company are not guarantees of future performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, the Company's ability to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies.

#### **OTHER INFORMATION**

Additional information on the Company is available is available under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com).

---

**CannAmerica Brands Corp.**  
Consolidated Financial Statements  
For the Years Ended March 31, 2021 and 2020

---

---

**INDEPENDENT AUDITORS' REPORT**

---

To the Shareholders and the Directors of CannAmerica Brands Corp.

**Opinion**

We have audited the consolidated financial statements of CannAmerica Brands Corp. and its subsidiaries (the "Company"), which comprise the consolidated statements of financial position as at March 31, 2021 and 2020, and the consolidated statements of operations and comprehensive loss, changes in deficiency and cash flows for the years then ended and the related notes comprising a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as at March 31, 2021 and 2020, and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

**Basis for Opinion**

We conducted our audits in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audits of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Emphasis of Matter - Material Uncertainty Related to Going Concern**

We draw attention to Note 1 of the consolidated financial statements, which describes matters and conditions that indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

**Other Information**

Management is responsible for the other information, which comprises the information included in the Company's Management Discussion and Analysis to be filed with the relevant Canadian securities commissions. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audits of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements**

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

## **Auditors' Responsibilities for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditors' report is Fernando J. Costa.

*Manning Elliott LLP*

CHARTERED PROFESSIONAL ACCOUNTANTS  
Vancouver, British Columbia  
October 5, 2021

**CannAmerica Brands Corp.**Consolidated statements of financial position  
(Expressed in Canadian dollars)

|   | Notes | March 31,<br>2021<br>\$ | March 31,<br>2020<br>\$ |
|---|-------|-------------------------|-------------------------|
| <b>Assets</b>                                 |       |                         |                         |
| <b>Current</b>                                |       |                         |                         |
| Cash  |       | 39,599                  | 15,973                  |
| Accounts receivable                           | 3     | 62,694                  | 139,031                 |
| Prepaid expenses and deposits                 |       | 141,398                 | 391,063                 |
|   |       | <b>243,691</b>          | <b>546,067</b>          |
| Investment in licensee                        | 4     | –                       | 886,689                 |
| Equipment                                     | 5     | 61,745                  | 60,844                  |
| Intangible assets                             | 6     | 1                       | 1,375,000               |
| <b>Total assets</b>                           |       | <b>305,437</b>          | <b>2,868,600</b>        |
| <b>Liabilities and deficiency</b>             |       |                         |                         |
| <b>Current liabilities</b>                    |       |                         |                         |
| Accounts payable and accrued liabilities      | 10    | 297,169                 | 884,764                 |
| Deferred revenue                              |       | 348,875                 | 293,457                 |
| Notes payable                                 | 7     | 3,846,128               | 4,040,917               |
| Loan payable                                  | 9     | 115,044                 | –                       |
| Debentures                                    | 8     | 467,545                 | 608,152                 |
| <b>Total liabilities</b>                      |       | <b>5,074,761</b>        | <b>5,827,290</b>        |
| <b>Deficiency</b>                             |       |                         |                         |
| Share capital                                 | 11    | 9,210,252               | 8,060,711               |
| Shares issuable                               |       | 118,521                 | 108,521                 |
| Contributed surplus                           |       | 2,829,187               | 2,759,676               |
| Deficit                                       |       | (17,098,050)            | (13,547,087)            |
| Accumulated other comprehensive income (loss) |       | 170,766                 | (340,511)               |
| <b>Total deficiency</b>                       |       | <b>(4,769,324)</b>      | <b>(2,958,690)</b>      |
| <b>Total liabilities and deficiency</b>       |       | <b>305,437</b>          | <b>2,868,600</b>        |

Going concern (Note 1)

Approved by the Board of Directors:

“Austin Sims”  
Austin Sims, Director

“Dan Anglin”  
Dan Anglin, CEO and Director

*The accompanying notes form an integral part of these consolidated financial statements.*

## CannAmerica Brands Corp.

Consolidated statements of operations and comprehensive loss  
(Expressed in Canadian dollars)

|  | Notes | Years ended March 31, |             |
|--|-------|-----------------------|-------------|
|  |       | 2021                  | 2020        |
|  |       | \$                    | \$          |
| <b>Revenue</b>   |       | <b>386,494</b>        | 915,096     |
| <b>Cost of sales</b>                                   |       | <b>58,079</b>         | 132,004     |
| <b>Gross margin</b>                                    |       | <b>328,415</b>        | 783,092     |
| <b>Expenses</b>  |       |                       |             |
| Advertising and promotion                              |       | <b>303,556</b>        | 747,772     |
| Bad debt recovery                                      |       | –                     | (29,433)    |
| Bank charges   |       | <b>2,492</b>          | 3,060       |
| Depreciation   | 5     | <b>19,439</b>         | 17,117      |
| Interest and accretion expense                         | 7,8   | <b>511,551</b>        | 340,461     |
| Office and administration                              |       | <b>38,995</b>         | 215,897     |
| Professional fees                                      |       | <b>249,082</b>        | 528,143     |
| Salaries and benefits                                  | 10    | <b>207,663</b>        | 713,701     |
| Share-based compensation                               | 10,11 | <b>494,511</b>        | 1,010,140   |
| <b>Loss before other items</b>                         |       | <b>(1,498,874)</b>    | (2,763,766) |
| <b>Other items</b>                                     |       |                       |             |
| Foreign exchange gain                                  |       | <b>(1,392)</b>        | (18,666)    |
| Loss on asset disposal                                 |       | –                     | 11,638      |
| Loss on investment                                     | 4     | <b>733,413</b>        | 148,963     |
| Impairment of intangible assets                        | 6     | <b>1,374,999</b>      | 1,725,000   |
| Loss on debt settlement                                | 11    | <b>41,620</b>         | –           |
| Gain on de-recognition of liabilities                  |       | <b>(89,298)</b>       | –           |
| Other income   |       | <b>(7,253)</b>        | –           |
| <b>Net loss for the year</b>                           |       | <b>(3,550,963)</b>    | (4,630,701) |
| Other comprehensive income (loss) for the year:        |       |                       |             |
| Item that may be reclassified subsequently to income   |       |                       |             |
| Unrealized gain (loss) on foreign currency translation |       | <b>511,277</b>        | (219,565)   |
| <b>Comprehensive loss for the year</b>                 |       | <b>(3,039,686)</b>    | (4,850,266) |
| Loss per common share – basic and diluted              |       | <b>(0.06)</b>         | (0.09)      |
| Weighted average number of common shares outstanding   |       | <b>56,039,579</b>     | 53,241,355  |

*The accompanying notes form an integral part of these consolidated financial statements.*

## CannAmerica Brands Corp.

Consolidated statements of changes in deficiency

(Expressed in Canadian dollars)

|  | Number of<br>shares | Share capital<br>\$ | Shares<br>issuable<br>\$ | Contributed<br>surplus<br>\$ | Accumulated<br>other<br>comprehensive<br>income (loss)<br>\$ | Deficit<br>\$       | Total<br>\$        |
|--|---------------------|---------------------|--------------------------|------------------------------|--|---------------------|--------------------|
| <b>Balance, March 31, 2019</b>           | <b>52,453,684</b>   | <b>7,873,211</b>    | <b>–</b>                 | <b>1,912,959</b>             | <b>(120,946)</b>   | <b>(8,916,386)</b>  | <b>748,838</b>     |
| Issuance of bonus shares                 | 1,250,000           | 187,500             | –                        | –                            | –  | –                   | 187,500            |
| Warrants issued pursuant to debentures   | –                   | –                   | –                        | 24,077                       | –  | –                   | 24,077             |
| Shares issuable                          | –                   | –                   | 108,521                  | –                            | –  | –                   | 108,521            |
| Share-based compensation                 | –                   | –                   | –                        | 822,640                      | –  | –                   | 822,640            |
| Net loss                                 | –                   | –                   | –                        | –                            | –  | (4,630,701)         | (4,630,701)        |
| Foreign currency translation adjustment  | –                   | –                   | –                        | –                            | (219,565)  | –                   | (219,565)          |
| <b>Balance, March 31, 2020</b>           | <b>53,703,684</b>   | <b>8,060,711</b>    | <b>108,521</b>           | <b>2,759,676</b>             | <b>(340,511)</b>   | <b>(13,547,087)</b> | <b>(2,958,690)</b> |
| Issuance of consulting shares            | 538,503             | 10,000              | 10,000                   | –                            | –  | –                   | 20,000             |
| Issuance of shares for debt settlement   | 6,732,903           | 383,659             | –                        | –                            | –  | –                   | 383,659            |
| Issuance of bonus shares                 | 5,000,000           | 425,000             | –                        | –                            | –  | –                   | 425,000            |
| Issuance of shares for debenture payment | 4,411,765           | 330,882             | –                        | –                            | –  | –                   | 330,882            |
| Share-based compensation                 | –                   | –                   | –                        | 69,511                       | –  | –                   | 69,511             |
| Net loss                                 | –                   | –                   | –                        | –                            | –  | (3,550,963)         | (3,550,963)        |
| Foreign currency translation adjustment  | –                   | –                   | –                        | –                            | 511,277  | –                   | 511,277            |
| <b>Balance, March 31, 2021</b>           | <b>70,386,855</b>   | <b>9,210,252</b>    | <b>118,521</b>           | <b>2,829,187</b>             | <b>170,766</b>   | <b>(17,098,050)</b> | <b>(4,769,324)</b> |

The accompanying notes form an integral part of these consolidated financial statements.

**CannAmerica Brands Corp.**Consolidated statements of cash flows  
(Expressed in Canadian dollars)

|  | Years ended March 31, |                  |
|--|-----------------------|------------------|
|  | 2021                  | 2020             |
|  | \$                    | \$               |
| <b>Operating activities</b>                                |                       |                  |
| Net loss   | (3,550,963)           | (4,630,701)      |
| Items not affecting cash                                   |                       |                  |
| Depreciation   | 19,439                | 17,117           |
| Bad debt recovery  | –                     | (29,433)         |
| Share-based compensation                                   | 494,511               | 1,010,140        |
| Consulting fees  | 20,000                | –                |
| Interest and accretion expense                             | 511,551               | 340,641          |
| Loss on disposal of asset                                  | –                     | 11,638           |
| Loss on investment   | 733,413               | 148,963          |
| Impairment of intangible assets                            | 1,374,999             | 1,725,000        |
| Loss on debt settlement                                    | 41,620                | –                |
| Gain on de-recognition of liabilities                      | (89,298)              | –                |
| Changes in non-cash working capital balances               |                       |                  |
| Accounts receivable  | 76,337                | 158,854          |
| Prepaid expenses and deposits                              | 249,665               | 478,224          |
| Deferred revenue   | 102,723               | (23,046)         |
| Accounts payable and accrued liabilities                   | (125,376)             | (33,293)         |
| <b>Net cash used in operating activities</b>               | <b>(141,419)</b>      | <b>(826,076)</b> |
| <b>Investing activities</b>                                |                       |                  |
| Purchase of equipment                                      | (22,552)              | (20,649)         |
| Proceeds from sale of investment                           | 70,088                | –                |
| <b>Net cash provided by (used in) investing activities</b> | <b>47,536</b>         | <b>(20,649)</b>  |
| <b>Financing activities</b>                                |                       |                  |
| Repayment of notes payable                                 | –                     | (404,765)        |
| Proceeds from debentures, net of cost                      | –                     | 558,840          |
| Proceeds from loan payable                                 | 115,044               | –                |
| Repayment of debentures                                    | (25,655)              | (60,647)         |
| Share issuable for license agreement                       | –                     | 70,936           |
| <b>Net cash provided by financing activities</b>           | <b>89,389</b>         | <b>164,364</b>   |
| <b>Effect of foreign currency translation on cash</b>      | <b>28,120</b>         | <b>(49,886)</b>  |
| <b>Decrease in cash</b>                                    | <b>(4,494)</b>        | <b>(732,247)</b> |
| <b>Cash, beginning of year</b>                             | <b>15,973</b>         | <b>748,220</b>   |
| <b>Cash, end of year</b>                                   | <b>39,599</b>         | <b>15,973</b>    |

Supplemental cash flow information (Note 15)

*The accompanying notes form an integral part of these consolidated financial statements*

## **CannAmerica Brands Corp.**

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### **1. NATURE AND CONTINUANCE OF OPERATIONS**

CannAmerica Brands Corp. (formerly Transform Capital Corp.) (“CannAmerica”) was incorporated in the province of British Columbia on March 13, 2017, under the Business Corporations Act of British Columbia. CannAmerica’s head office and its registered and records office is located at 10th Floor, 595 Howe Street, Vancouver, British Columbia, V6C 2T5.

These consolidated financial statements comprise the financial statements of CannAmerica and its wholly-owned subsidiaries (collectively referred to as the “Company”). On May 30, 2018, CannAmerica entered into an agreement with the shareholders of CannAmerica Holdings Corp. (“CannAmerica Holdings”) whereby 100% of the common shares and warrants of CannAmerica Holdings were exchanged for common shares of CannAmerica (the “CannAmerica Holdings Acquisition”).

CannAmerica Holdings was incorporated in the Province of British Columbia on December 11, 2017, under the Business Corporations Act of British Columbia and owns a portfolio of brands in the medical and recreational cannabis space in the United States through its wholly-owned subsidiary DAFF International, LLC (“DAFF”). The Company’s principal business is to build on and maximize the value of its brands by promoting, marketing and licensing these brands through various distribution channels, including dispensaries, wholesalers and distributors. The Company currently has brand licensing agreements with licensees in the states of Colorado, Nevada, Oklahoma and Massachusetts. On October 15, 2018 the Company listed on the Canadian Securities Exchange (the “CSE”) under ticker symbol “CANA”.

These consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at March 31, 2021 the Company has an accumulated deficit of \$17,098,050 and has generated negative cash flows from operations. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company not continue as a going concern. The proposed business of the Company involves a high degree of risk. Additional funds will be required to enable the Company to pursue its initiatives and the Company may be unable to obtain such financing on satisfactory terms. Furthermore, there is no assurance that the business will be profitable. These factors indicate the existence of a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. Management continues to monitor the situation and is assessing the impact on the Company.

## **CannAmerica Brands Corp.**

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### **2. SIGNIFICANT ACCOUNTING POLICIES**

#### **Statement of compliance**

These consolidated financial statements, including comparatives, have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). These consolidated financial statements were authorized for issue by the Board of Directors on October 5, 2021.

#### **Basis of presentation and measurement**

These consolidated financial statements include the accounts of the Company and its subsidiaries on a historical cost basis except for certain financial instruments which are measured at fair value. Historical cost is generally based upon the fair value of the consideration given in exchange for assets.

#### **Basis of consolidation**

These consolidated financial statements comprise the financial statements of the Company and its wholly-owned subsidiaries. Subsidiaries are those entities which the Company controls by having the power to govern the financial and operational policies of the entity. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a company’s share capital. All intercompany transactions and balances have been eliminated.

|                            | Percentage ownership interest |      |
|----------------------------|-------------------------------|------|
|                            | 2021                          | 2020 |
| CannAmerica Holdings Corp. | 100%                          | 100% |
| DAFF International, LLC    | 100%                          | 100% |

#### **Functional and presentation currency**

Items included in the consolidated financial statements of the Company and its wholly owned subsidiaries are measured using the currency of the primary economic environment in which the entity operates. The functional currency of CannAmerica and CannAmerica Holdings is the Canadian dollar. The functional currency of the foreign operation, DAFF, is the US dollar. These consolidated financial statements are presented in Canadian dollars.

Foreign currency transactions are translated into the functional currency at the exchange rate as at the date of the transaction. At each statement of financial position date, monetary assets and liabilities in foreign currencies are translated using the period end foreign exchange rate. Non-monetary assets and liabilities in foreign currencies are translated using the historical rate. All gains and losses on translation of these foreign currency transactions are included in profit and loss.

The results and financial position of a subsidiary that has a functional currency different from the presentation currency are translated into the presentation currency as follows:

- Assets and liabilities are translated at the closing rate at the reporting date;
- Income and expenses for each income statement are translated at average exchange rates for the period; and
- All resulting exchange differences are recognized in other comprehensive income as cumulative translation adjustments.

On consolidation, exchange differences arising from the translation of the net investment in a foreign operation are taken to accumulated other comprehensive loss. When a foreign operation is sold, such exchange differences are recognized in profit or loss as part of the gain or loss on sale.

## **CannAmerica Brands Corp.**

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### **2. SIGNIFICANT ACCOUNTING POLICIES (cont'd)**

#### **Significant accounting estimates and judgments**

The preparation of these consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statement and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the financial position reporting date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

#### Significant accounting estimates

- i. the measurement of deferred income tax assets and liabilities;
- ii. inputs used in impairment calculations; and
- iii. inputs used in share-based compensation

#### Significant accounting judgments

- i. the evaluation of the Company's ability to continue as a going concern;
- ii. assessment of indications of impairment; and
- iii. assessment of whether an acquisition is a business combination or an asset acquisition

#### **Business combinations and goodwill**

Acquisitions of businesses are accounted for using the acquisition method. At the acquisition date the identifiable assets acquired and the liabilities assumed are recognized at their fair value, except deferred tax assets or liabilities, which are recognized and measured in accordance with IAS 12 *Income Taxes*. Subsequent changes in fair values are adjusted against the cost of acquisition if they qualify as measurement period adjustments. The measurement period is the period between the date of the acquisition and the date where all significant information necessary to determine the fair values is available and cannot exceed 12 months. All other subsequent changes are recognized in the consolidated statements of operations and comprehensive loss.

The purchase price allocation process resulting from a business combination requires management to estimate the fair value of identifiable assets acquired including intangible assets and liabilities assumed including any contingently payable purchase price obligation due over time. The Company uses valuation techniques, such as forecasted future net cash flows discounted to present value and the mergers and acquisitions method. These valuations are closely linked to the assumptions used by management on the future performance of the related assets and the discount rates applied. The determination of fair value involves making estimates relating to acquired equipment, intangible assets and contingent consideration.

## **CannAmerica Brands Corp.**

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### **2. SIGNIFICANT ACCOUNTING POLICIES (cont'd)**

#### **Business combinations and goodwill (cont'd)**

In certain situations, goodwill or a bargain purchase gain may result from a business combination. Goodwill is measured as the excess of the consideration transferred over the net amounts of the identifiable assets acquired and the liabilities assumed. Goodwill is measured at historical cost and is evaluated for impairment annually or more often if events or circumstances indicate there may be an impairment. Impairment is determined for goodwill by assessing if the carrying value of a CGU, including the allocated goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs to sell and the value in use. Impairment losses recognized in respect of a CGU are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGU. Any goodwill impairment is recorded in income in the period in which the impairment is identified. Impairment losses on goodwill are not subsequently reversed. Acquisition related costs are recognized in the consolidated statements of comprehensive loss as incurred.

#### **Income taxes**

Deferred tax assets and liabilities are recognized where the carrying amount of an asset or liability differs from its tax base, except for taxable temporary differences arising on the initial recognition of goodwill and temporary differences arising on the initial recognition of an asset or liability in a transaction which is not a business combination and at the time of the transaction affects neither accounting nor taxable profit or loss.

Recognition of deferred tax assets for unused tax losses, tax credits and deductible temporary differences is restricted to those instances where it is probable that future taxable profit will be available against which the deferred tax asset can be utilized. At the end of each reporting period the Company reassesses unrecognized deferred tax assets. The Company recognizes a previously unrecognized deferred tax asset to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

#### **Share capital**

Common shares are classified as equity. Transaction costs directly attributable to the issue of common shares and common share warrants are recognized as a deduction from equity. Common shares issued for non-monetary consideration are measured based on their market value at the date the common shares are issued.

For unit offerings of common shares and warrants, the proceeds are allocated between the common shares and share purchase warrants using the residual method, allocating fair value to the common shares and then the residual to the share purchase warrants.

#### **Earnings (loss) per share**

The Company presents basic and diluted earnings (loss) per share data for its common shares, calculated by dividing the earnings (loss) attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined by adjusting the earnings attributable to common shareholders and the weighted average number of common shares outstanding for the effects of all dilutive potential common shares. However, the calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive. Basic and diluted loss per share is the same for the periods presented.

## **CannAmerica Brands Corp.**

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### **2. SIGNIFICANT ACCOUNTING POLICIES (cont'd)**

#### **Impairment of long-lived assets**

Long-lived assets, including intangible assets are reviewed for impairment at each statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit, or "CGU"). The recoverable amount of an asset or a CGU is the higher of its fair value, less costs to sell, and its value in use. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss by the amount by which the carrying amount of the asset exceeds the recoverable amount. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded had no impairment loss been recognized previously.

#### **Intangible assets**

Intangible assets with finite useful lives are recorded at cost less accumulated amortization and accumulated impairment losses and are amortized over their estimated useful lives. Estimated useful lives of intangible assets are the shorter of the economic life and the period the right is legally enforceable. The assets' useful lives are reviewed, and adjusted if appropriate, at each statement of financial position date.

Intangible assets with indefinite useful lives are comprised of the portfolio of cannabis brands and are carried at cost less accumulated impairment losses. Intangible assets with indefinite lives are not amortized but are tested annually for impairment. Any impairment of intangible assets is recognized in the statement of operations and comprehensive loss but increases in intangible asset values are only recognized to the extent that they reverse any previously recognized impairment losses.

#### **Equipment**

The Company depreciates the cost of equipment over their estimated useful lives from the date they are available for use at the following annual rates:

|           |                                  |
|-----------|----------------------------------|
| Equipment | 3-5 Years – Straight Line Method |
|-----------|----------------------------------|

#### **Revenue recognition**

The Company licenses its intellectual property, brands and products to customers and charges upfront license fees and a fixed fee per unit shipped. For the upfront license fees revenue is recognized over the term of the license agreement as the Company satisfies its performance obligation over time. For the fixed fee per unit shipped revenue is recognized when the goods are shipped which is the point in time when the Company satisfies its performance obligation. Revenue excludes sales tax and is recorded net of discounts and an allowance for estimated returns unless the terms of the sale are final. Payment received from customers in advance of meeting the performance obligations are recorded as deferred revenue and subsequently recognized as revenue when the performance obligations are satisfied.

#### **Cost of sales**

Cost of sales includes the expenses incurred to acquire and produce inventory for sale, including product costs, inbound freight and duty costs, as well as provisions related to product shrinkage, excess or obsolete inventory, or lower of cost and net realizable value adjustments as required. The Company carries minimal amounts of inventory.

## CannAmerica Brands Corp.

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### 2. SIGNIFICANT ACCOUNTING POLICIES (cont'd)

#### Share-based compensation

The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company's estimate of equity instruments that will eventually vest. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For share-based payments granted to non-employees the compensation expense is measured at the fair value of the good and services received except where the fair value cannot be estimated in which case it is measured at the fair value of the equity instruments granted. The fair value of share-based compensation to non-employees is periodically re-measured until counterparty performance is complete, and any change therein is recognized over the period and in the same manner as if the Company had paid cash instead of paying with or using equity instruments. Consideration paid by employees or non-employees on the exercise of stock options is recorded as share capital and the related share-based compensation is transferred from contributed surplus to share capital.

#### Financial instruments

The classification and measurement of financial assets is based on the Company's business models for managing its financial assets and whether the contractual cash flows represent solely payments of principal and interest ("SPPI"). Financial assets are initially measured at fair value plus, in the case of financial assets not at fair value through profit and loss ("FVTPL") transaction costs.

Financial assets are subsequently measured at either:

- i. amortized cost;
- ii. fair value through other comprehensive income ("FVTOCI"); or
- iii. at fair value through profit or loss ("FVTPL").

Financial liabilities are generally classified and measured at fair value at initial recognition and subsequently measured at amortized cost.

The following table summarizes the classification of the Company's financial instruments:

|                              |                |
|------------------------------|----------------|
| <b>Financial assets</b>      |                |
| Cash                         | FVTPL          |
| Accounts receivable          | Amortized cost |
| Investment in licensee       | FVTPL          |
| <b>Financial liabilities</b> |                |
| Accounts payable             | Amortized cost |
| Notes payable                | Amortized cost |
| Loan payable                 | Amortized cost |
| Debentures                   | Amortized cost |

IFRS 9 uses an expected credit loss impairment model which is applicable to financial assets measured at amortized cost where any expected future credit losses are provided for, irrespective of whether a loss event has occurred as at the reporting date.

#### Accounting standards and amendments issued but not yet effective

Accounting standards or amendments to existing accounting standards that have been issued but have future effective dates are either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements.

## CannAmerica Brands Corp.

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

### 3. ACCOUNTS RECEIVABLE

|                           | 2021          | 2020    |
|---------------------------|---------------|---------|
|                           | \$            | \$      |
| Trade accounts receivable | 49,333        | 96,679  |
| GST and taxes recoverable | 13,361        | 42,352  |
|                           | <b>62,694</b> | 139,031 |

The trade accounts receivable is net of allowance for expected credit losses. As at March 31, 2021, the allowance for expected credit losses of \$261,202 (2020: \$294,685) reflects the Company's best estimate of expected credit losses inherent in the trade accounts receivable and is determined based on known troubled accounts, historical experience, and other available information.

### 4. INVESTMENT IN LICENSEE

The Company previously owned a 10% equity investment in a licensee which holds a cannabis processing license under the Maryland Medical Cannabis Commission and an option to purchase an additional 30% equity investment in the licensee for USD\$2,500,000. During the year-ended March 31, 2021, the Company sold their equity investment in this licensee and realized a loss of \$733,413.

|   | Total     |
|---|-----------|
|   | \$        |
| Balance, March 31, 2019                 | 946,071   |
| Unrealized loss on investment           | (148,963) |
| Foreign currency translation adjustment | 89,581    |
| Balance March 31, 2020                  | 886,689   |
| Foreign currency translation adjustment | (83,188)  |
| Proceeds received                       | (70,088)  |
| Realized loss on investment             | (733,413) |
| <b>Balance, March 31, 2021</b>          | <b>-</b>  |

### 5. EQUIPMENT

|   | Total         |
|---|---------------|
|   | \$            |
| <b>Cost</b>                             |               |
| Balance, March 31, 2019                 | 61,767        |
| Additions                               | 20,649        |
| Foreign currency translation adjustment | (1,454)       |
| Balance, March 31, 2020                 | 80,962        |
| Net additions                           | 22,552        |
| Foreign currency translation adjustment | (2,212)       |
| Balance, March 31, 2021                 | 101,302       |
| Balance, March 31, 2019                 | 4,997         |
| Disposal of asset                       | (1,996)       |
| Depreciation                            | 17,117        |
| Balance, March 31, 2020                 | 20,118        |
| Depreciation                            | 19,439        |
| Balance, March 31, 2021                 | 39,557        |
| Balance, March 31, 2020                 | 60,844        |
| <b>Balance, March 31, 2021</b>          | <b>61,745</b> |

## CannAmerica Brands Corp.

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### 6. INTANGIBLE ASSETS

On May 18, 2018, the Company entered into an agreement with the shareholders of DAFF to acquire 100% of the common shares of DAFF. As part of the DAFF Acquisition, the Company acquired a portfolio of medical and recreational cannabis brands which have an indefinite useful life.

|                                | Total<br>\$ |
|--------------------------------|-------------|
| Balance March 31, 2019         | 3,100,000   |
| Impairment                     | (1,725,000) |
| Balance March 31, 2020         | 1,375,000   |
| Impairment                     | (1,374,999) |
| <b>Balance, March 31, 2021</b> | <b>1</b>    |

During the year ended March 31, 2021, the Company completed its annual assessment of the recoverable amount of the intangible assets and determined that the recoverable amount was lower than the carrying value. Accordingly, the Company recorded an impairment loss of \$1,374,999 (2020: \$1,725,000) to recognize the economic uncertainty of its branded products and write-down the intangible assets to their estimated recoverable amount.

### 7. NOTES PAYABLE

As part of a previous year acquisition, the Company acquired promissory notes, including a promissory note due to HWH Holdings LLC in the amount of US\$3,650,000. The note bears interest at 9% per annum, with interest beginning to accrue on June 1, 2018 and was due on November 15, 2019, which was the date 13 months after the date on which any affiliate that directly or indirectly held the interest in the Company becomes a reporting public company under applicable Canadian Law. During the year ended March 31, 2019, the Company repaid US\$1,200,000 of the balance owing and recorded interest expense of \$128,551. On December 9, 2019, the Company and HWH Holdings LLC amended the loan agreement to continue to incur interest at 9% per annum with no set maturity date. During the year ended March 31, 2021, the Company repaid \$nil (2020: US\$301,748) of the balance owing and recorded interest expense of \$266,158 (2020: \$230,927). As of March 31, 2021, the balance of the principal and accrued interest is \$3,468,878 (US\$2,758,551) (2020: \$3,615,307).

The Company also acquired US\$650,000 in notes payable as part of a previous year acquisition. During the year ended March 31, 2019, the Company repaid US\$350,000. The notes payable are non-interest bearing and were due on November 15, 2019, which was the date 13 months after the date on which any affiliate that directly or indirectly held the interest in the Company and becomes a reporting public company under applicable Canadian Law. As of March 31, 2021, the balance of the principal is \$377,250 (US\$300,000) (2020: \$425,610).

### 8. DEBENTURES

On August 30, 2019, the Company completed a non-brokered private placement of unsecured debentures (the "Debentures") for gross proceeds of \$663,350. The Debentures have a term of fifteen (15) months and bear interest at a rate of 12% per annum. The subscribers also received 3,316,750 warrants to purchase common shares of the Company (the "Warrants"). Each Warrant entitles the holder to purchase one common share of the Company at an exercise price of \$0.1582303 per common share for a period of 36 months.

## CannAmerica Brands Corp.

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### 8. DEBENTURES (cont'd)

The Company is required to repay the Debentures in 12 equal monthly installments of 1/12 of the principal amount plus accrued interest (the "Repayment Amount") beginning four months plus one day after the date of issuance of the Debentures. The Company has the option of making the Repayment Amount in common shares. The number of common shares payable would be equal to the Repayment Amount divided by the issue price of 85% of the volume-weighted average price of the Company's common shares for 5 consecutive trading days before the repayment date ("Price"). The Company may not repay the Debentures with common shares if the Price is less than \$0.10 per common share or if there has been an event of default. If an event of default occurs as defined in the debenture agreement, the rate of interest will increase to 25% per annum. Any event of default is waivable in writing by the subscriber.

The Company recorded the \$634,249 liability component of the Debentures based on the estimated fair value of the liability component and allocated the remaining residual of \$29,101 to the Warrants.

The Company incurred total issuance costs of \$114,509 of which \$109,486 was allocated to the Debentures and \$5,024 was allocated to the Warrants. The total issuance costs include \$10,000 of common shares issuable to the finder.

Per the terms of an agreement entered into on February 23, 2021, between the parties, the Company agreed to repay \$300,000 of the Debentures in common shares at a deemed price of \$0.068. Additionally, the 3,316,750 Warrants were cancelled in exchange for 4,411,765 new warrants to purchase common shares of the Company (the "New Warrants"). Each New Warrant entitles the holder to purchase one common share at an exercise price of 0.08 per common share for a period of five years.

|                                  | \$               |
|----------------------------------|------------------|
| Balance, March 31, 2019          | -                |
| Principal amount of Debentures   | <b>663,350</b>   |
| Discount allocated to Warrants   | <b>(29,101)</b>  |
| Issuance costs                   | <b>(109,486)</b> |
| Repayments                       | <b>(60,647)</b>  |
| Interest and accretion           | <b>144,036</b>   |
| Balance, March 31, 2020          | <b>608,152</b>   |
| Repayments                       | <b>(325,655)</b> |
| Interest and accretion           | <b>185,048</b>   |
| <b>Balance at March 31, 2021</b> | <b>467,545</b>   |

### 9. LOAN PAYABLE

On May 5, 2020, the Company entered into a loan agreement with a third party under the Small Business Administration Payroll Protection Program and borrowed a total of US\$91,486 which is forgivable subject to the certain conditions. Subject to the agreement, the loan will be forgivable if the Company spends the funds on payroll, rent, and utilities for the subsequent eight weeks with appropriate supporting documents. As at March 31, 2021, there was \$115,044 (US\$91,486) in total consisting of principal of loan. Interest of 1% accrues on the loan during the time between the disbursement of the loan and SBA remittances of the forgiveness amount. Loan payments are deferred for the first six months and the loan is set to mature two years after its initial grant.

## CannAmerica Brands Corp.

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### 10. RELATED PARTY TRANSACTIONS AND BALANCES

All related party transactions have occurred in the normal course of operations. Related party transactions occur and are recorded at the exchange amounts agreed between the parties.

For the year ended March 31, 2021, the Company was charged \$82,592 in salaries (2020: \$145,417) by the CEO of the Company. At March 31, 2021 there is a balance of \$10,843 (2020: \$86,715) payable to the CEO.

For the year ended March 31, 2021, the Company was charged \$103,840 (2020: \$61,659) in salaries by the COO of the Company. At March 31, 2021, there is a balance of \$7,720 (2020: \$nil) payable to the COO.

For the year ended March 31, 2021, the Company was charged \$34,823 in salaries (2020: \$145,417) by the CCO of the Company. At March 31, 2021, there is a balance of \$nil (2020: \$77,773) payable to the CCO.

For the year ended March 31, 2021, the Company was charged \$69,163 in management fees (2020: \$85,122) by the CFO of the Company. At March 31, 2021, there is a balance of \$6,288 (2020: \$14,187) payable to the CFO.

For the year ended March 31, 2021, the Company recorded sales of \$39,825 (2020: \$nil) to a company under common control. At March 31, 2021, there is a balance of \$35,865 (2020: \$nil) receivable from this company.

#### Key management personnel compensation

Key management is comprised of the Company's directors and executive officers. The Company incurred the following key management compensation charges during the years ended March 31, 2021 and 2020:

|                                      | 2021    | 2020      |
|--------------------------------------|---------|-----------|
|                                      | \$      | \$        |
| Salaries, bonuses, fees and benefits | 290,418 | 437,614   |
| Share based compensation             | 401,011 | 636,500   |
|                                      | 691,429 | 1,074,114 |

### 11. SHARE CAPITAL

The Company has an unlimited number of common shares without par value authorized for issuance. As at March 31, 2021 the Company had 70,386,855 common shares issued and outstanding (2020: 53,703,684) of which 1,650,600 were held in escrow (2020: 3,301,200). As at March 31, 2021, the Company has \$98,521 of shares issuable to a licensee under the terms of the license agreement.

On August 14, 2019, the Company issued 1,250,000 bonus shares to certain directors, officers, and employees which had a fair value of \$187,500 included as share-based compensation.

On September 2, 2020, the Company issued 538,503 common shares to consultants for services performed which had a fair value of \$10,000 and recorded an additional \$10,000 of shares issuable for a total of \$20,000 included as consultant expense.

On January 26, 2021, the Company issued 4,715,957 common shares which had a fair value of \$212,218 in a debt settlement agreement for \$221,650 of accounts payable and recorded a gain on debt settlement of \$9,432.

## CannAmerica Brands Corp.

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

### 11. SHARE CAPITAL (cont'd)

On February 18, 2021, the Company issued 2,016,946 common shares which had a fair value of \$171,440 in a debt settlement agreement for \$151,271 of accounts payable and recorded a loss on debt settlement of \$20,169.

On February 18, 2021, the Company issued 5,000,000 bonus shares to certain directors, officers, and employees which had a fair value of \$425,000 included as share-based compensation.

On February 23, 2021, the Company issued 4,411,765 common shares which had a fair value of \$330,882 for repayment of \$300,000 of debentures owed (Note 8) and recorded a loss on debt settlement of \$30,882.

#### Warrants

Movements in the number of warrants outstanding and their related weighted average exercise prices are as follows:

|                             | Number of warrants | Weighted average exercise price \$ |
|-----------------------------|--------------------|------------------------------------|
| Outstanding, March 31, 2019 | 5,914,646          | 0.64                               |
| Granted                     | 3,316,750          | 0.16                               |
| Outstanding, March 31, 2020 | 9,231,396          | 0.47                               |
| Granted                     | 4,411,765          | 0.08                               |
| Expired and cancelled       | (9,231,396)        | (0.47)                             |
| Outstanding, March 31, 2021 | 4,411,765          | 0.08                               |

The following summarizes information about the outstanding share purchase warrants exercisable to acquire common shares of the Company as at March 31, 2021:

| Number of warrants outstanding | Exercise price \$ | Expiry date       |
|--------------------------------|-------------------|-------------------|
| 4,411,765                      | 0.08              | February 23, 2026 |

As at March 31, 2021, the Company has an obligation to issue 167,692 finders warrants in connection with the Debentures detailed in Note 8.

#### Stock option plan

The Company has adopted a rolling incentive stock option plan (the "Option Plan") which provides that the Board of Directors of the Company may from time to time, in its discretion, and in accordance with the applicable stock exchange's requirements, grant to Directors, officers, employees or consultants to the Company, non-transferable options to purchase common shares. Pursuant to the Option Plan, the number of common shares reserved for issuance will not exceed 15% of the issued and outstanding common shares of the Company. Options granted under the Option Plan can have a maximum exercise term of 10 years from the date of grant. Vesting terms will be determined at the time of grant by the Board of Directors.

## CannAmerica Brands Corp.

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

### 11. SHARE CAPITAL (cont'd)

On April 13, 2020, the Company granted 250,000 stock options to a director of the Company. The stock options are exercisable at price of \$0.05 per share for a period of five years from the grant date. The stock options vest over a period of two years with 25% vesting immediately and an additional 25% vesting every 6 months thereafter. The fair value of the stock options on grant date was calculated to be \$3,703 using the Black Scholes option pricing model based on a share price of \$0.015, a risk-free interest rate of 1.77%, an expected volatility of an estimated volatility of 240%, an expected dividend rate of nil and an expected life of five years.

On December 15, 2020, the Company granted 250,000 stock options to a director of the Company. The stock options are exercisable at price of \$0.05 per share for a period of five years from the grant date. The stock options vest over a period of two years with 25% vesting immediately and an additional 25% vesting every 6 months thereafter. The fair value of the stock options on grant date was calculated to be \$9,922 using the Black Scholes option pricing model based on a share price of \$0.04, a risk-free interest rate of 1.77%, an expected volatility of an estimated volatility of 240%, an expected dividend rate of nil and an expected life of five years.

Movements in the number of options outstanding and their related weighted average exercise prices are as follows:

|                             | Number of<br>options | Weighted<br>average<br>exercise price<br>\$ |
|-----------------------------|----------------------|---|
| Outstanding, March 31, 2019 | 7,575,000            | 0.44  |
| Cancelled                   | (825,000)            | 0.38  |
| Forfeited                   | (275,000)            | 0.60  |
| Outstanding, March 31, 2020 | 6,475,000            | 0.44  |
| Granted                     | 500,000              | 0.05  |
| Cancelled                   | (1,575,000)          | 0.28  |
| Outstanding March 31, 2021  | 5,400,000            | 0.41  |

The following summarizes information about the outstanding stock options exercisable to acquire common shares of the Company as at March 31, 2021:

| Number of options | Outstanding   |   | Exercisable       |   |   |
|-------------------|---|---|-------------------|---|---|
|                   | Weighted<br>average<br>remaining<br>contractual<br>life (years) | Weighted<br>average<br>exercise price<br>\$ | Number of options | Weighted<br>average<br>remaining<br>contractual life<br>(years) | Weighted<br>average<br>exercise price<br>\$ |
| 2,600,000         | 2.2   | 0.30  | 2,600,000         | 2.2   | 0.30  |
| 2,000,000         | 2.8   | 0.60  | 2,000,000         | 2.8   | 0.60  |
| 300,000           | 2.9   | 0.60  | 300,000           | 2.9   | 0.60  |
| 250,000           | 4.0   | 0.05  | 125,000           | 4.0   | 0.05  |
| 250,000           | 4.7   | 0.05  | 62,500            | 4.7   | 0.05  |
| 5,400,000         |   | 0.41  | 5,087,500         |   | 0.41  |

## CannAmerica Brands Corp.

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

### 12. INCOME TAXES

The tax effect of significant temporary differences (computed by applying the Canadian federal and provincial statutory rate), which comprise deferred income tax assets and liabilities, are as follows:

|   | 2021      | 2020        |
|---|-----------|-------------|
|   | \$        | \$          |
| Canadian statutory income tax rate                | 27.00%    | 27.00%      |
| Income tax recovery at statutory rate             | (958,759) | (1,250,289) |
| Tax effect of:                                    |           |             |
| Permanent and other differences                   | (77,004)  | 273,032     |
| Difference in foreign tax rates                   | 3,870     | 7,601       |
| Change in unrecognized deferred income tax assets | 1,031,893 | 969,656     |
| Deferred income tax recovery                      | -         | -           |

The significant components of deferred income tax assets and liabilities are as follows:

|  | 2021        | 2020        |
|--|-------------|-------------|
|  | \$          | \$          |
| Deferred income tax assets (liabilities)             |             |             |
| Non-capital losses carried forward                   | 1,793,933   | 1,338,170   |
| Capital assets                                       | 9,770       | 5,439       |
| Share issuance costs                                 | 58,608      | 84,820      |
| Intangible assets                                    | 1,539,804   | 1,168,554   |
| Investment in licensee                               | -           | (226,761)   |
| Total gross deferred income tax assets (liabilities) | 3,402,115   | 2,370,222   |
| Unrecognized deferred income tax assets              | (3,402,115) | (2,370,222) |
| Net deferred income tax assets (liabilities)         | -           | -           |

As at March 31, 2021, the Company has non-capital losses of approximately \$4,653,000 (2020: \$3,950,000) in Canada and \$2,098,000 (2020: \$908,000) in the United States that may be carried forward to apply against future years' taxable income, subject to final determination by taxation authorities and expiring between 2038 and 2041.

## CannAmerica Brands Corp.

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

### 13. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of inputs used in making the measurements. The hierarchy is summarized as follows:

- Level 1 quoted prices (unadjusted) in active markets for identical assets and liabilities
- Level 2 inputs that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices) from observable market data
- Level 3 inputs for assets and liabilities not based upon observable market data

The following financial instruments are presented at fair value on a recurring basis:

|      | Carrying<br>value<br>\$ | March 31, 2021 |         |         |
|------|-------------------------|----------------|---------|---------|
|      |                         | Level 1        | Level 2 | Level 3 |
|      |                         | \$             | \$      | \$      |
| Cash | 39,599                  | 39,599         | -       | -       |

The Company's financial instruments are exposed to certain financial risks, including credit, liquidity, currency and interest rate risk.

#### Credit risk

Credit risk arises from cash held with banks and financial institutions, as well as credit exposure on outstanding accounts receivables. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The Company seeks to limit its exposure to this risk by holding its cash in reputable financial institutions. The Company does not have significant credit risk with respect to customers.

#### Liquidity risk

The following table details the Company's expected remaining contractual cash flow requirements for its financial liabilities on repayment or maturity periods. The amounts presented are based on the contractual undiscounted cash flows and may not agree with the carrying amounts in the consolidated statements of financial position:

| As at March 31, 2021 | Up to 1 year | 1 - 5 years | Total     |
|----------------------|--------------|-------------|-----------|
| Accounts payable     | 297,169      | -           | 297,169   |
| Notes payable        | 3,846,128    | -           | 3,846,128 |
| Loan payable         | 115,044      | -           | 115,044   |
| Debentures           | 467,545      | -           | 467,545   |
|                      | 4,725,886    | -           | 4,725,886 |

The Company expected to repay the notes payable with proceeds from a private placement financing prior to the maturity date and is continuing to pursue financing. If the Company is unsuccessful with obtaining financing, or unable to otherwise repay the notes payable the note holders could foreclose on the collateral.

#### Currency risk

Currency risk is the risk that changes in foreign exchange rates will affect the Company's income or the value of its holdings of financial instruments. The functional currency of DAFF is the US Dollar and the majority of transactions are transacted in the US Dollar. In addition, all DAFF financial liabilities are denominated in the US Dollar. The Company does not undertake currency hedging activities to mitigate its foreign currency risk. The impact on the Company's profit or loss resulting from a 10% fluctuation in foreign exchange rates would be approximately \$27,000 (2020: \$56,000).

## **CannAmerica Brands Corp.**

Notes to the Consolidated Financial Statements

Years ended March 31, 2021 and 2020

(Expressed in Canadian dollars)

---

### **13. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (cont'd)**

#### **Interest rate risk**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market interest rates. The Company has debt instruments however the interest rate is fixed and therefore the related interest rate risk is minimal.

### **14. CAPITAL MANAGEMENT**

The Company's objectives when managing its capital are to safeguard its ability to continue as a going concern, to meet its capital expenditures for its continued operations, and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. The Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares, enter into debt facilities, or acquire or dispose of assets. The Company is not subject to externally imposed capital requirements.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company's capital management approach in the period. The Company considers its shareholders' equity as capital.

### **15. SUPPLEMENTAL CASH FLOW INFORMATION**

|   | Years ended March 31, |      |
|---|-----------------------|------|
|   | 2021                  | 2020 |
|   | \$                    | \$   |
| Income taxes paid                         | -                     | -    |
| Interest paid                             | -                     | -    |
| Shares issued for repayment of debentures | 300,000               | -    |



**CANNAMERICA BRANDS CORP.  
CORPORATE DIRECTORY**

**OFFICERS**

Dan Anglin  
President  
Chief Executive Officer  
Diana Anglin  
Chief Financial Officer  
Chief Operating Officer  
Corporate Secretary

**DIRECTORS**

Dan Anglin  
Austin Sims  
Diana Anglin

**AUDITORS**

Manning Elliott LLP  
1700 1030 West Georgia Street  
Vancouver, B.C.  
V6E 2Y3

**LEGAL COUNSEL**

DuMoulin Black, LLP  
Vancouver, British Columbia  
Canada

**CORPORATE OFFICE**

10th Floor, 595 Howe Street  
Vancouver, British Columbia  
Canada V6C 2T5  
Contact: [info@cannamericabrands.com](mailto:info@cannamericabrands.com)  
Website: <http://www.cannamericanbrands.com>

**REGISTERED OFFICE**

DuMoulin Black, LLP  
10th Floor, 595 Howe Street  
Vancouver, British Columbia  
Canada V6C 2T5

**RECORDS OFFICE**

DuMoulin Black, LLP  
10th Floor, 595 Howe Street  
Vancouver, British Columbia  
Canada V6C 2T5

**REGISTRAR AND TRANSFER AGENT**

National Securities Administrators Ltd.  
Endeavour Trust Corporation  
760 - 777 Hornby Street  
Vancouver, British Columbia  
Canada V6Z 1S4

**SHARE LISTING**

Canadian Securities Exchange (“CSE”)  
Symbol: CANA  
CUSIP No: 13766C